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ABSTRACT

NITRIC OXIDE RELEASE FROM POLY(LACTIC-CO-GLYCOLIC ACID)
NANOPARTICLES AND TITANIUM ALLOY

By
Nina Allyn Reger
August 2017

Dissertation supervised by Dr. Ellen S. Gawalt
Current methods for the treatment of bacterial infection involve the use of
systemic antibiotics, which are high concentrations of antibiotics delivered over a long
period time. Unfortunately, the use of systemic antibiotics can cause harmful side effects
to the patient and increases the possibility for antibiotic resistance. The delivery of
antibiotics or alternative antimicrobial compounds, such as nitric oxide, directly to the
site of infection would decrease the amount of antibiotic necessary to treat a bacterial
infection.
Poly (lactic-co-glycolic acid)/polyvinyl alcohol nanoparticles and a titaniumaluminum-vanadium metal oxide alloy implant were surface functionalized to deliver
nitric oxide. Polymer nanoparticles can be used to deliver nitric oxide to patients with
extensive bacterial infection in the lung, while the modified metallic implant can be used

iv

to prevent bacterial cell adhesion onto the surface post implantation. These surfaces were
covalently modified with S-nitrosothiols, and characterized using infrared and ultravioletvisible spectroscopic techniques. The attachment of the S-nitrosothiol to the nanoparticle
surface resulted in a nmole of nitric oxide per milligram of nanoparticles release under
physiological conditions, while the modified titanium alloy released a nmole of nitric
oxide per cubic centimeter. The low concentration of nitric oxide released from the
nanoparticle and titanium alloy surfaces reduced Escherichia coli growth, indicating that
S-nitrosothiol remains active against bacteria after covalent immobilization to the surface.
The S-nitrosothiol modified titanium alloy inhibited Staphylococcus epidermidis growth,
indicating effectiveness against a gram-positive microbe. Combining both nitric oxide
releasing materials with tetracycline, a commonly prescribed antibiotic, increased the
effectiveness of the antibiotic, which allows for lower doses of antibiotics to be used.
Thus, the polymer nanoparticles and titanium alloy developed here have the capability of
delivering an antibiotic alternative, nitric oxide, directly to the site of an infection,
reducing the need for harmful systemic antibiotics and the possibility of antibiotic
resistance.
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Chapter 1. Background
1.1 Introduction
Each year in the United States, upwards of 2 million individuals contract
antibiotic resistant infections. Approximately 23,000 of those affected succumb to these
bacterial and fungal infections annually.1 The economic burden of these illnesses cost the
United States $20 billion in additional healthcare costs.2 These infections are a result of
inappropriate antibiotic prescribing, dosing, and ultimately overuse.3 Antibiotics are
found in the water we drink and the food we eat, as it is often used as a dietary
supplement for food animals to promote growth.2, 3 The continuous exposure to these
antibiotics fuels the potential for a bacterial species to become resistant.3 Additionally,
30-50% of the antibiotics prescribed to treat an infection are not needed (i.e. viral versus
bacterial infection) or are not effective as prescribed (i.e. the bacterial species present).2, 3
The current development of new classes of antibiotics is limited, and thus appropriate
usage of current antibiotics or alternative antimicrobial compounds are required to ensure
the long-term effective treatment for bacterial infections.4

1.2 Antibiotic Resistance and Biofilms
1.2.1 Antibiotic Resistance
In 2010, twenty-two doses of antibiotics were prescribed per person in the United
States.3 These systemic antibiotics are administered typically in pill form and when
given, can cause toxic effects to cells and organs.5 This delivery method often requires
high doses to ensure the antibiotic reaches the specific site of infection within the body.6
For example, vancomycin is typically administered intravenously to a surgical patient
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two hours before a procedure begins to ensure the antibiotic is present at the surgical
site.7 Additionally, high dosages for prolonged use can contribute to antibiotic resistance,
leading to increased treatment costs, increased risk of side effects, longer hospital stays,
and higher mortality rates.3, 7, 8 Localized delivery of antibiotics, in combination with
antibiotic alternatives like antimicrobial peptides and small molecules, would decrease
the high concentrations of antibiotics required to treat infections, reducing the possibility
of antibiotic resistance.9
Bacterial cells within a population can become resistant to antibiotics through the
following four mechanisms: antibiotic modification, decreased uptake, active site
alterations, or alternate target production (Figure 1.1a).10 Ultimately, these resistant
mechanisms can be horizontally transferred as genes through plasmids, spontaneous
mutation, or inherited from other bacteria within the population (Figure 1.1b).3 In
antibiotic modification, the antibiotic is changed via enzymatic cleavage. For example,
increased β-lactamase production by a bacterial cell cleaves β-lactam antibiotics (i.e.
penicillin derivatives), inactivating the antibiotic.10 In decreased uptake, bacteria can
pump antibiotics out of the cytoplasm through efflux transport pumps located within the
cell membrane.10 In active site alterations, bacterial cells can undergo changes to the cell
membrane, which is a target of many antibiotics.10 Some strains of Escherichia coli and
Staphylococcus aureus undergo changes in lipid or protein composition of the cell’s outer
membrane, making diffusion of antibiotics difficult.11-13 Lastly, bacteria can produce
alternative antibiotic targets, typically an enzyme or protein, which are resistant to
antibiotic inhibition. The cell can continue to produce the original sensitive bacterial
enzyme, which remains unaffected.14 This method of resistance is well known in
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Methicillin Resistant S. aureus (MRSA) and Vancomycin Resistant S. aureus (VRSA).10,
12

(a)
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= Antibiotic

Antibiotic Modification

Active Site Alterations
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→

→
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→
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Resistant bacteria
Non-living bacteria

Live bacteria
Mutant bacteria

Figure 1.1: (a) Mechanisms of antibiotic resistance10 and (b) horizontal gene transfer of
resistance in a bacterial population.

1.2.2 Bacterial Biofilms
Biofilm formations of gram-positive and gram-negative bacteria, as well as fungi,
have been isolated from immunocompromised patients (i.e. cystic fibrosis)15,

16

and

medically implanted devices such as catheters, prosthetic heart valves, cardiac

3

pacemakers, and joint replacements.17-20 Typical pathogens isolated include, but are not
limited to: S. aureus, Staphylococcus epidermidis, E. coli, Pseudomonas aeruginosa, and
Candida albicans. The pathogenicity of these microorganisms is enhanced by the ability
to form a biofilm on both biotic and abiotic surfaces, as well as antimicrobial resistance.21
Biofilms are structured microbial communities that are irreversibly attached to
either a living or non-living surface.22 Initially, individual, free-floating planktonic cells
adhere to a surface. This is followed by the propagation stage, where cells spread across
the surface and then enter a maturation stage, where the biofilm produces and is encased
in an extracellular matrix. This excreted extracellular matrix, composed primarily of
polysaccharides, proteins, and lipids,23 retains nutrients for the microbial cells and
provides protection from antimicrobial treatments and the host immune system.17, 22, 23
Cells within a biofilm display a distinctly different phenotype than their planktonic
counterparts17,

22, 23

and are typically 1,000-fold more resistant than bacteria in a

planktonic state, making treatment of these infections difficult.24
The formation of a biofilm is controlled through the production of signaling
molecules, called quorum-sensing molecules. Quorum sensing molecules are
extracellular metabolites that relay information about cell density and can affect cell
physiology.25, 26 This cell-to-cell signaling can lead to a coordinated dispersal event in
which cells from the biofilm re-enter the planktonic state and colonize new surfaces
within the body.22,

27

An accumulation of these small, diffusible molecules in the

extracellular environment are essential for cell-to-cell communication, biofilm
maintenance, and multicellular dispersion (Figure 1.2).28
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Planktonic Cells

Initial Attachment to Surface

Extracellular Matrix

Dispersion

Growth and Division
Signaling
Molecules
Mature Microcolony Formation

Figure 1.2: Steps in biofilm formation on a surface include: irreversible attachment of
planktonic cells, bacteria replication and production of an extracellular matrix, and
dispersal of planktonic cells.

1.2.2.1 Biofilms in Cystic Fibrosis Patients
Since

biofilms

are

not

limited

to

abiotic

surfaces,

they

affect

immunocompromised patients such as those with cystic fibrosis (CF). CF is a genetic
disease that is characterized by gastrointestinal and pulmonary dysfunction that requires
continuous medication and medical intervention.29 These dysfunctions are due to the
excessive build up of thick mucus within the digestive tract and lungs. Due to the
inability to remove excess mucus, bacteria located within the respiratory tract form
biofilms on the surface of lung, leading to chronic infections.15, 16, 29 P. aeruginosa, a
gram-negative bacteria, is the microbe that is typically isolated from the lungs of CF
patients.16 In a healthy individual, the sterile environment of the lower respiratory tract is
due to the natural production of periciliary fluid, a fluid that helps the lung clear mucus,
microorganisms, and other debris.30,

31

Those with CF display excretions that lack

5

periciliary fluid, which causes endothelial damage and the extensive build up of mucus in
the lungs.30, 31
Current therapies for patients with CF involve both preventative and active
treatment methods. Methods to facilitate the removal of the thick mucus within a CF lung
are the most common preventative approaches. Here, patients can undergo chest
physiotherapy, postural drainage, and high frequency chest compressions using a
compression vest.29 The disruption of the mucus creates an environment less conducive
to biofilm formation, while improving respiratory function by promoting ciliary
clearance.29 Active treatments are necessary when CF lung is already infected by biofilms
and require the use of systemic antibiotics.29 Unfortunately, systemic dosages of
antibiotics often do not eradicate P. aeruginosa biofilms from the lung due to biofilm
structure and acquired resistance from long term use.16 Over time, these chronic
infections become more severe and difficult to manage and many CF patients are placed
on a lung transplant list. Of those that do not receive new lungs, 80 to 95% of patients die
as a result of lung damage and respiratory failure.32 Thus, the localized delivery of
antimicrobial compounds directly to the lung of these patients may help reduce biofilm
formation.

1.2.2.2 Biofilms on Metallic Medical Devices
Of the roughly 2.6 million annual orthopedic implant surgeries in the United
States, approximately 112,000 result in infection.33 These orthopedic devices are
typically made of stainless steel, titanium, or titanium alloys and when infected with
bacteria or fungi they often need to be removed.33 Implant removal is typically
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complicated by tissue or bone ingrowth.33,

34

The best approach to eradicate implant

infections is to remove the initial implant, systemically treat the infection, and then insert
a new implant.35, 36 These revision surgeries are painful, risky, and costly to the patient.33,
34

Although implant materials are sterilized prior to placement via aseptic technique,
approximately 90% of all implants show pathogenic microorganisms on the surface postimplantation.33 In vivo, implants are capable of absorbing host proteins, making the
surface more favorable for microorganism attachment and subsequent biofilm growth.33
S. aureus and S. epidermidis account for nearly 60% of all implant acquired infections.33,
37

Since these bacteria are local to the surgical site, limiting initial bacterial attachment

onto the implant surface may help to reduce biofilm formation.34

1.3. Nitric Oxide: An Alternative Antimicrobial Compound
1.3 .1 Nitric Oxide
In 1992, Science named nitric oxide (NO) as the “molecule of the year,” for its
role in biological messaging and signaling. Once thought to be a toxic chemical found in
cigarettes and smog, NO is actually an effective regulator in the nervous, immune, and
cardiovascular systems.38, 39 The list of processes that NO is associated with includes, but
is not limited to: vasodilation,40, 41 cancer,42, 43 host infection,44, 45 and wound repair.46

1.3.2 Endogenous Nitric Oxide Production
Nitric oxide is produced endogenously in the body by the nitric oxide synthase
(NOS) enzyme. NOS oxidizes the guanidine group of L-arginine; through the loss of five
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electrons, NO is produced along with a stoichiometric equivalent amount of Lcitrulline.39, 47 The sustained formation of NO from NOS in macrophages and monocytes
gives these cells the capability of being cytostatic and cytotoxic to various viruses,
bacteria, fungi, and tumor cells.48 Macrophage production of glutathione, cysteine,
peroxides, and superoxide, increases the antimicrobial effect of NO as NO readily reacts
with thiols, such as those in glutathione and cysteine, to form S-nitrosothiols (RSNOs),
capable of storing NO for longer periods of time.48 NO reacted with water, oxygen, and
superoxide produce reactive intermediates, such as other radicals (NO2), anions of nitrite
(NO2-) and nitrate (NO3-), various oxides (ex. N2O3), and peroxides (ONOO-)48. At lower
pH, nitrous acid can form from accumulating NO2-, which can itself release NO when
simultaneously oxidized and reduced. Individuals suffering from various bacterial or viral
infections show elevated levels of nitrate in blood plasma, a byproduct of NO oxidation,
indicating that cells are actively producing NO during infection.49

1.3.3 Exogenous Nitric Oxide Donors
Since endogenously produced NO plays such a crucial role in various biological
systems, the delivery of exogenous NO holds promise for various biomedical applications
including cardiovascular dilation, antimicrobial therapies, and tumoricidal treatments.
Various donors have been synthesized to allow for controlled release of NO and include
but are not limited to: nitrites, NO – metal complexes, nitroamines, N-diazeniumdiolates
(NONOates), and RSNOs.44, 48 Each donor has properties and release profiles that make
them unique and useful in various applications, but the most well studied donors are
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NONOates and RSNOs (Table 1.1).50 These donors have functional groups available for
linking to various biomaterials, including nanoparticles and hydrogels.
Table 1.1: Comparison of the properties of two common NO donors: NONOates and
RSNOs.51

Formation Conditions

N-Diazeniumdiolates
(NONOates)
High Pressures of NO gas

Decomposition Triggers

H 3O +

Light, heat, Cu2+, thiols

Release kinetics

Highly tunable based on pH

Dependent on triggers

Toxicity

Carcinogenic nitrosamines

None

Charged

Yes

No

Storage Capacity

2 moles NO/ mole 2° amine

1 mole NO/ mole thiol

Light Sensitivity

No

Yes

Source

Exogenous

Endogenous

1.3.3.1

S-Nitrosothiols (RSNOs)
Acidic

N-Diazeniumdiolates

NONOates are the most widely used donors in NO releasing biomaterials.52 These
donors release two moles of NO per parent compound under physiological conditions
(i.e. 37°C, pH 7.4). NONOates are formed via the reaction of a secondary amine with
high pressures of NO gas.53 Successful NONOate formation requires the presence of a
second basic residue, such as a metal alkoxide base (i.e. sodium methoxide), to
deprotonate the secondary amine within the diazeniumdiolate backbone.51,

54

The

diazeniumdiolate can then perform a nucleophilic attack of the NO.51, 54 The cation from
the alkoxide base serves to stabilize the resulting anionic NONOate (Figure 1.3).53, 54
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Figure 1.3: The formation of N-diazeniumdiolates. Two moles of NO are released from
each NONOate species; these moieties are highlighted in purple.51, 54
Upon protonation of the NO moiety on the NONOate donor, the NO is released.53
However, the structure of the amine precursor directly affects the kinetics of this NO
release. For example, diethylenetriamine NONOate (DETA/NONOate) has a half-life
(t1/2) of 20 hours while diethylamine NONOate (DEA/NONOate) has a t1/2 of 2-4
minutes.55, 56 The difference in NO release is due to hydrogen bonding stabilization from
additional amines.51 Although NONOates are spontaneous NO donors under
physiological conditions and have attractive amine functionalities, they are not produced
naturally by the body and can decompose into potentially carcinogenic nitrosamines.57-60

1.3.3.2

S-nitrosothiols

RSNOs are attractive NO donors, as the body naturally produces a variety of
RSNOs in human plasma, airway lining fluid, macrophages, neutrophils, and other sites
relevant to the immune system, and are therefore non-toxic.44 Many small molecules and
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proteins containing a thiol group can be nitrosylated, with the most common RSNO
compounds of: S-nitrosocysteine, S-nitrosoglutathione, S-nitrosocysteamine, and Snitroso-N-acetylpencillamine (Figure 1.4).61 Molecules and proteins that contain thiol
groups are preferably nitrosylated over those that contain nitrogen, carbon, and oxygen44.
RSNO compounds are stable under physiological conditions (i.e. pH 7.4, 37°C), in the
absence of light, and in the presence of transition metal chelators.44, 62
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Figure 1.4: S-nitrosocysteine (a), S-nitrosoglutathione (b), S-nitrosocysteamine (c), and
S-nitroso-N-acetylpenicillamine (d) RSNO NO donors.
RSNOs can be formed in vitro by reacting a thiol-containing compound with a
nitrosylating agent, such as alkyl nitrite, dinitrogen trioxide, or nitrous acid.63 The
formation of these compounds is confirmed using ultraviolet-visible radiation (UV-Vis),
as RSNO species absorb in both the visible (nN → π*; 550-600 nm) and ultraviolet (no →
π*; 330-350 nm) ranges.64, 65
The decomposition mechanisms, as well as formation mechanisms, of these
compounds make RSNOs excellent for the storage and transport of NO (Figure 1.5). The
decomposition of a RSNO compound is due to the homolytic cleavage of the S–N bond,
causing the release of NO and a thiyl radical.47,

62

This decomposition is triggered

thermally, through photoinitiation, or through the addition of metal ions.47, 62 When the
temperature of a RSNO is changed or is exposed to irradiation at the absorption
maximum, the resulting decomposition releases NO and the resulting thiyl radical.47, 62, 64
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Due to the very short life span of NO (3-5 seconds), it reacts almost immediately with
oxygen (or superoxide in vivo) and becomes oxidized to form other reactive intermediates
such as NO2-, OONO-, or NO3-, as previously mentioned.47 NO can also be released from
RSNOs through the addition of copper (II) ions (Cu2+).62 Cu2+ readily reacts with thiolate
(RS–), and through reduction, copper (I) ions (Cu+) are generated. The Cu+ reacts with the
RSNO species to trigger the release of thiolate and NO, while simultaneously
regenerating Cu2+. Buffers have enough Cu2+ to facilitate NO release from RSNO and
ascorbate can also be added as a reducing agent in cases where the thiolate ion is low in
concentration.62 RSNO compounds can also undergo transnitrosation, which involves the
transfer of NO+ from a RSNO to an unreacted free thiol.62 This process impacts RSNO
stability and results in the formation of a new R’SNO and thiol compound. This
phenomenon is more relevant in vivo, where this transfer can modify cysteine residues
and alter enzymes and active sites of proteins.62
R S
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R SH
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R

S

N

O

hν or Δ

R'

SH

R S

+

N O
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Figure 1.5: RSNO formation and resulting NO release mechanisms.66
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1.3.4 Antibacterial Effect of Nitric Oxide
The antibacterial effect of NO is due to the nitrosative and oxidative stress it
causes in a virus or bacteria cell. NO can react with oxygen, water, and superoxide, as
mentioned previously, to form highly reactive nitrogen and oxygen intermediates.67 The
NO and the formed intermediates overwhelm the cell’s capability to remove these
species, leading to damage of bacterial deoxyribonucleic acid (DNA), lipids, and
proteins.67 The reactive nitrogen species are thought to cause the deamination of
deoxynucleotides in DNA, disrupt the reactive sites of proteins, and damage cellular
membranes through lipid peroxidation (Figure 1.6).68 NO and the resulting reactive
species can also trigger biofilm dispersal. Here, planktonic bacterial cells are released
from the biofilm and are then able to colonize other abiotic or biotic surfaces.69

NO + O2

NO2 + NO

N2O3 + Met

Trp
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RSNO
RNNO

Extracellular Space
Bacterial Membrane

NO + O2

OONO

H

Intracellular Space
HOONO

NO2 + OH

Lipid Peroxidation

Protein Damage

DNA Cleavage

Figure 1.6: Cellular targets of endogenously and exogenously delivered NO (Image
adapted from Carpenter et al.70).
Recent work by Barraud et al. has shown that nanomolar (nM) concentrations of
NO have been shown to decrease biomass and increase planktonic cell biomass of single
and mixed biofilms containing E. coli, S. epidermidis, Vibrio cholera, C. albicans, and P.
13

aeruginosa.67, 71 A 500 nM concentration of the NO donor sodium nitroprusside (SNP)
removed 38% of an established E. coli biofilm and 60% of the multi-species biofilm.71
Additionally, Barraud and coworkers observed that nM concentrations of NO coupled
with an antibiotic increased the effectiveness of the antibiotic through synergistic
effects.67 The mechanism of biofilm dispersal is poorly understood, but is linked to
nutrient availability, cell lysis within the biofilm, and release of quorum sensing
molecules.67, 69 Upon dispersal, bacteria in a planktonic state are then more susceptible to
antibiotic treatment.22

1.4

Current Approaches to Nitric Oxide Delivery
The potential of the antibacterial capability of NO is limited by storage and

delivery methods.45, 72 Traditionally, NO has been delivered as a gas or through SNP, but
NO delivery by nanoparticles and hydrogels is of recent interest due to the ability to
deliver NO directly to the infection site.70

1.4.1 Nitric Oxide Delivery by Nanoparticles
Nanoparticles have been developed to deliver drugs and small molecules by
injection, orally, and through inhalation.73-76 Inhaled nanoparticles have the potential to
deliver drugs to patients with CF.77 There are several publications that discuss NO
modified nanoparticles but a majority are based on gold and silica nanoparticles.24, 45, 57,
72, 78-80

Polizzi and coworkers synthesized NONOate functionalized gold cluster

nanoparticles capable of releasing micromole per milligram (µmole/mg) amounts of
NO.79 The effectiveness of these particles was not tested against bacterial cultures or
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biofilms, but sheds light on the true ability of NO release from nanoparticles. Perhaps the
most well studied NO delivery vehicles are silica nanoparticles. Hetrick et al. modified
aminopropyltrimethoxysiloxane nanoparticles with a NONOate moiety, capable of
reducing P. aeruginosa, E. coli, S. aureus, S. epidermidis, and C. albicans biofilm growth
by 99.9%.24, 45 Martinez and coworkers observed 100% killing of MRSA bacteria in the
presence of NO releasing silicate nanoparticles81 while hydrogel/glass silicate
nanoparticles synthesized by Friedman and coworkers showed 75-100% antibacterial
activity against E. coli, Klebsiella pneumoniae, P. aeruginosa, and Streptococcus
pyogenes.82 Although these nanoparticles are effective at biofilm eradication, Slomberg et
al. showed cytotoxic effects of silica/NONOate nanoparticles against mouse fibroblasts.83
Although these nanoparticles are antimicrobial and possess anti-biofilm properties, silica
nanoparticles are not approved for use by the Food and Drug Administration (FDA) and
thus have a limited application for drug delivery in humans.57
While most publications focus on the use of silica nanoparticles, few utilize
polymer nanoparticles to deliver NO.

84, 85

Poly(DL-lactic-co-gycolic acid) (PLGA), an

FDA approved, biocompatible polymer was used by Yoo et al. and Nurhasni et al. to
synthesize NO releasing nanoparticles.84-87 Yoo and coworkers utilized a water in oil in
water (w/o/w) emulsion technique to encapsulate DETA/NONOate within the PLGA
nanoparticles. Although these nanoparticles were not tested against bacterial cultures,
they deliver µmole/mg amounts of NO in vitro.85 The PLGA nanoparticles developed by
Nurhasni et al. also encapsulated a NONOate donor using an oil in water (o/w)
emulsification technique. These nanoparticles released µmole/mg amounts of NO in vitro
and showed approximately 99% killing of MRSA and P. aeruginosa.84 Although these
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nanoparticles are non-cytotoxic and can ultimately be used in drug delivery applications
in vivo, they utilize potential carcinogenic NONOate chemistry and not naturally derived
RSNO donors. Thus, there is a need for a new biodegradable and biocompatible polymer
nanoparticle that releases NO from RSNO donors.
This project aims to improve upon current delivery methods of NO by utilizing
RSNOs and biocompatible delivery vehicles. PLGA nanoparticles were functionalized
with S-nitrosocysteamine at the surface to release amounts of NO that were bacteriostatic
to bacterial cultures. These nanoparticles eliminate the issues of carcinogenic NONOates
and utilize materials approved for use by the FDA. These nanoparticles could be effective
for NO delivery to patients suffering from CF.

1.4.2 Nitric Oxide Delivery by Metal Implants
While nanoparticles have the potential to deliver NO directly to an infected lung,
modification of metal surfaces to release NO can be used in medical device applications.
Direct modification of a metallic surface to release NO was reported by Gallo and
Mani.88 Here, cobalt-chromium stents were modified with phosphonoacetic acid,
followed by DETA/NONOate. Although these stents were not tested against bacterial
cultures, the modified metal surface released micromolar (µM) amounts of NO in vitro.88
Metallic implants that have been developed to release NO utilize polymeric
coatings. Nablo and coworkers generated a stainless steel implant material coated with a
silica sol-gel containing a NONOate donor.89 These coatings released picomole per cubic
centimeter per second (pmole cm-2 s-1) amounts of NO over 24 hours, and reduced
Staphylococcal bacterial adhesion onto the coated surface.89 Holt et al. coated the surface
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of commercially pure titanium fixation pins utilizing a silica xerogel containing a
NONOate functionality. Like Nablo and coworkers, these titanium pins released pmole
cm-2 s-1 amounts of NO and reduced bacterial adhesion 48 days post implantation in a
mouse model.89,

90

The cytotoxicity of these NONOate silica gel coatings was not

discussed, and could pose limited applications for in vivo applications.89, 90
In this project, a titanium alloy implant material was functionalized at the surface to
release NO through a RSNO, S-nitroso-penicillamine. This donor eliminates the issues of
carcinogenic NONOates, while being bacteriostatic against gram-positive and gramnegative bacteria. The metal surface developed here is the first example of direct release
of NO for bacterial inhibition from a metallic surface without the need for a polymeric
coating.

1.5 Summary
Although systemic antibiotic usage continues to be the gold standard for the
treatment of bacterial infections, the high antibiotic dosages required to achieve
antimicrobial efficiency can lead to harmful toxicity and increased bacterial resistance.5
Additionally, these high doses of antibiotics are ineffective against pathogenic biofilms
that plague immunocompromised individuals and those with implanted medical devices.
Localized delivery of antibiotics or antimicrobial alternatives, like NO, is needed to
overcome the effects of antibiotic resistance. Antimicrobial delivery of NO through
nanoparticles and metallic implant materials has shown to be effective against grampositive and gram-negative bacteria and fungi. These current delivery methods hold
promise to deliver NO directly to the site of infection but unfortunately, have focused on
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the use of potentially carcinogenic NONOates and scaffolds not approved for in vivo use
by the FDA. The nanoparticles and titanium alloy developed here release NO amounts
that are bacteriostatic against planktonic bacterial species and non-cytotoxic to
mammalian cells, ideal for site specific delivery.
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Chapter 2. Synthesis, Functionalization, Characterization, and
Antimicrobial Activity of Poly(Lactic-co-Glycolic Acid) Nitric Oxide
Releasing Nanoparticles
2.1 Introduction
PLGA nanoparticles are a promising platform technology for the controlled
release of small molecule drugs.1 These nanoparticles are formed through emulsification
and solvent evaporation techniques that encapsulates the molecule of choice into the
center of the nanoparticle. Ultimately, the release of the encapsulated small molecule
occurs either through diffusion of the molecule through the PLGA backbone, erosion of
the polymeric material, or by combination of diffusion and erosion.1, 2 The advantage of
using PLGA, in combination with a polymeric surfactant such as polyvinyl alcohol
(PVA), over other platforms (i.e. silica nanoparticles), is that PLGA and PVA are
biodegradable and biocompatible.1-4 PLGA degraded in vivo, enzymatically or nonenzymatically, produces lactic acid and glycolic acid products that are also biocompatible
and non-toxic.1, 2
The formation of these polymer nanoparticles requires the presence of a
surfactant, which itself is present on the exterior of the nanoparticle, while the PLGA
remains on the inside of the nanoparticle. An oil/water emulsification technique is
commonly used in nanoparticle synthesis, where the PLGA is dissolved first in solvent
(oil phase) and then added to a water phase (surfactant in water). The two phases are
homogenized together to produce microspheres and during the solvent evaporation
process, the microspheres decrease in size as the solvent diffuses from the interior of the
particle.1 The nanoparticles developed in this project utilize PVA as a surfactant, which
presents free hydroxyl groups on the exterior of the nanoparticle, while the PLGA
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remains on the interior of the nanoparticle (Figure 2.1a).3-5 These free hydroxyls are
advantageous in that they can be functionalized by organic acid thin films (Figure 2.1b).6,
7

These formed organic thin films mimic those of self-assembled monolayers (SAMs)

which are ordered molecular assemblies formed spontaneously via chemisorption onto a
specific substrate and are composed of a head group, alkyl chain, and a tail group.8, 9 The
head group is thought to bind to an oxide rich surface through either ionic or covalent
interactions.8 The tail group presents a reactive group that controls the interfacial
properties and allows for modification to release a variety of bioactive compounds, such
as DNA,3 antibiotics,6, 7 antimicrobial peptides,10 and cell adhesion peptides.11, 12
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Figure 2.1: PLGA nanoparticles with PVA as the surfactant presents free hydroxyls at
the surface (a) which allows for the formation of organic thin films at the surface (b).
Functionalizing the surface of the nanoparticle has the advantage of direct
delivery of bioactive compounds and is not dependent on the diffusion or the slow in vivo
degradation of the PLGA and PVA. To date, there have been no surface functionalized
PLGA nanoparticles developed that are capable of releasing NO. A majority of the
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nanoparticles formulated to deliver NO focus on the use of silica nanoparticles and
potentially carcinogenic NONOates.13-17 Here, PLGA/PVA nanoparticles were modified
at the surface to release NO using organic thin films. A reaction at the thin film terminus
provides an interface for further surface reactions in which an NO donor could be
immobilized onto the surface. The functionalized nanoparticles were tested for
antimicrobial properties and cytotoxic effects.

2.2 Materials
PLGA (50:50; 16.5-22 kDa; I.V. = 0.66-0.80) was purchased from Polysciences.
Anhydrous dichloromethane (DCM, 99.9%) was purchased from Acros Organics and
used as received. Cysteamine (95%), 16-phosphonohexadecanoic acid (COOH-Pa, 97%),
N-Hydroxysuccinimide

(NHS),

1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide

hydrochloride (EDC), D-penicillamine (98-101%), sodium nitrite (NaNO2, 99.999% trace
metal), and Dulbecco’s phosphate buffered saline (PBS, pH=7.4) were purchased from
Sigma-Aldrich and used as received. Diethylenetriaminepentaacetic acid (DTPA,
>99.0%) was purchased from Fluka. Polyvinyl alcohol (PVA, 86-89% hydrolyzed, low
molecular weight) and hydrochloric acid (HCl) was obtained from Fisher Scientific.
Methanol (100%) and deionized water (ddH2O) were obtained from Duquesne
University. The nitrate/nitrite colorimetric assay kit was purchased from Cayman
Chemical Company.
Lennox Luria-Bertani (LB) Media was obtained from MP Biomedicals, Inc. and
two capsules were dissolved per 50 mL of ddH2O and autoclaved before use.
Tetracycline hydrochloride and tryptic soy broth (TSB) was obtained from Fisher
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Scientific. Vancomycin hydrochloride (from Streptomyces orientalis) was obtained from
Sigma-Aldrich. E. coli (ATCC® 25922), S. epidermidis (ATCC® 14990), 3T3 Swiss
Albino mouse embryo fibroblasts (CCL-92), Dulbecco’s Modified Eagle’s Media
(DMEM), fetal bovine serum (FBS), and penicillin/streptavidin were obtained from
American Type Culture Collection (ATCC). Trypsin/EDTA was purchased from LONZA
(Walkersville, MD). The LIVE/DEAD® Cytotoxicity/Viability Assay Kit for mammalian
cells was purchased from Life Technologies/Fisher Scientific.

2.3 Methods
2.3.1 Nanoparticle Synthesis
PLGA nanoparticles were prepared using an o/w solvent-evaporation technique
with slight modifications from Mainardes et al. (Figure 2.2).18 Approximately 25
milligrams (mg) of PLGA was added to 1 milliliter (mL) of DCM and was allowed to
dissolve for one hour. A stock solution of 1% PVA was prepared by dissolving solid
PVA in ddH2O, under heating and stirring conditions to facilitate the dissolving of the
polymer. Ten mL of 0.3% PVA was added to the organic solution containing PLGA to
form the o/w emulsion. The resulting emulsion was vortexed for 1 minute and then
homogenized at 25,000 rpm for 2 minutes. The single emulsion was stirred for 4 hours to
allow the DCM to evaporate. The particles were recovered by centrifugation (16,000 rcf)
and washed twice with dH2O to remove excess PVA. The resulting nanoparticles were
reconstituted in 5% w/v sucrose and lyophilized using a Labconco Freeze Dry System.
Previous studies have shown that PLGA/PVA particle size and zeta potential remain
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consistent after lyophilization.3 The lyophilized nanoparticles were stored in a desiccator
until further reaction and characterization.

0.3% PVA solution

Addition of
Surfactant

PLGA
CH2Cl2

Homogenization
(15000 rpm)

w/o Emulsification

Stirring
PLGA

Ultracentrifugation
Solidification
(Diffusion and Evaporation)

16000 rcf

PLGA

PLGA
PLGA

PLGA
PLGA

PLGA
PVA

Figure 2.2: O/w emulsion technique for the synthesis of PLGA nanoparticles utilizing
0.3% PVA as the surfactant. These polymer nanoparticles were formed via an o/w
emulsification and solvent evaporation technique.

2.3.2 S-Nitrosothiol Immobilization
2.3.2.1

Thin-Film Surface Modification

Prior to surface modification, the lyophilized nanoparticles were rinsed with PBS
and recovered by ultracentrifugation to remove the sucrose cryoprotectant. Nanoparticles
were suspended in a solution of 1 mM COOH-Pa in 25% methanol/ 75% water. The
particles were allowed to react with COOH-Pa for 6 hours with gentle shaking at room
temperature. The resulting suspension was centrifuged at 16,000 rcf for 20 minutes and
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the collected nanoparticle pellet was dried in a desiccator overnight before further
characterization and functionalization.

2.3.2.2 S-Nitrosocysteamine Modified Nanoparticles
S-Nitrosocysteamine (SNC), a RSNO NO donor, was immobilized onto the
nanoparticle surface using a one-step approach (Scheme 2.1). SNC was generated by
reacting cysteamine with acidified nitrite. Briefly, 100 mM of cysteamine was reacted
with 100 mM NaNO2 and 250 mM HCl in the presence of 100 µM DTPA in an ice bath
for 1 hour and 15 minutes, while protected from light (Scheme 2.1a).19 DTPA serves as a
metal chelator and removes metals from the solution to avoid a premature release of NO
from the solution.20 Once formed, SNC was attached to the nanoparticle surface using
carbodiimide coupling. To form the amide bond, 200 µL of SNC, 200 µL 0.2 M NHS in
ddH2O, and 100 µL 0.2 M EDC in ddH2O was added to the COOH-Pa modified particles
and allowed to react for 24 hours in the dark under gentle shaking conditions (Scheme
2.1b).21 The nanoparticles were collected by ultracentrifugation and allowed to dry in a
desiccator at room temperature overnight before further experiments.
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Scheme 2.1: The synthesis of the RSNO donor, SNC (a) and the reaction sequence for
the immobilization of SNC to the surface of PLGA nanoparticles (b).

2.3.2.3

S-Nitroso-Penicillamine Modified Nanoparticles

S-Nitroso-penicillamine was immobilized onto the nanoparticle surface using a
two-step approach (Scheme 2.2). The S-nitroso-penicillamine donor contains both amine
and carboxylic acid functionalities within the molecule and thus the COOH-Pa
nanoparticles were first activated with EDC and NHS, in the absence of the donor, to
avoid any cross-linking within the RSNO donor (Scheme 2.2a). The COOH-Pa modified
nanoparticles were reacted with 0.2 M NHS in ddH2O and 100 µL 0.2 M EDC in ddH2O
for 7 hours in the dark under gentle shaking conditions. The particles were collected via
ultracentrifugation and dried in a desiccator at room temperature overnight.
S-nitroso-penicillamine was generated by reacting penicillamine with acidified
nitrite. Briefly, 100 mM of penicillamine was reacted with 100 mM NaNO2 and 250 mM
HCl in the presence of 100 µM DTPA in an ice bath for 1 hour and 15 minutes, protected
from light (Scheme 2.2b).19 Once formed, 300 µL of S-nitroso-penicillamine added to the
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EDC/NHS activated COOH-Pa nanoparticles and were allowed to react for 7 hours in the
dark under gentle shaking conditions.21 The nanoparticles were collected by
ultracentrifugation and allowed to dry in a desiccator at room temperature overnight
before further experiments.
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Scheme 2.2: The synthesis of S-nitroso-penicillamine (a) and the reaction sequence for
the immobilization of S-nitroso-penicillamine to the surface of PLGA nanoparticles (b).

2.3.3 Characterization of Nanoparticles
2.3.3.1

Infrared Spectroscopy

A Nexus 470 Fourier Transform Infrared (FTIR, Thermo Fisher) spectrometer
with a diffuse reflectance infrared Fourier transform (DRIFT) attachment was used to
analyze the functional groups present at the surface of the nanoparticles both before and
after functionalization with SNC and S-nitroso-penicillamine. A Thermo Nicolet
Attenuated Total Reflectance (ATR) attachment was used to analyze solid powder

33

samples. Each sample was analyzed under inert conditions with 256 scans (4000 to 400
cm-1) and a resolution of 4 cm-1.

2.3.3.2

Ultraviolet-Visible Spectroscopy

Liquid SNC and S-nitroso-penicillamine and modified nanoparticle solutions were
scanned from 800 nm to 250 nm using a Varian UV-Vis spectrophotometer (Agilent
Technologies, USA) to determine the wavelength of maximum absorption. The RSNO
donors were diluted 1:1 with ddH2O to reduce signal saturation. To reduce colloidal
interferences, the SNC and S-nitroso-penicillamine modified nanoparticles were
dissolved in 2:1 DCM: methanol.22,

23

The attachment of both RSNO donors was

confirmed through comparison of the UV-Vis spectrum of the liquid donor versus the
UV-Vis spectrum of the dissolved nanoparticles.

2.3.3.3

Scanning Electron Microscopy

Morphological characteristics, such as shape and homogeneity, of unmodified and
surface modified nanoparticles were examined using a Hitachi S-3400N-II scanning
electron microscope (SEM) in backscatter electron mode. Micrographs were collected
between 800-1100x magnification with a 5.00 kV accelerating voltage, 80.0 volt (V)
probe current, and a working distance of 10.0 millimeters (mm). Samples were analyzed
under variable pressure instead of full vacuum to reduce polymer melting.
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2.3.3.4

Nanoparticle Size and Zeta Potential

The nanoparticle size, polydispersity index (PDI), and zeta potential were
determined using dynamic light scattering (DLS) on a Nano-ZS Zetasizer (Malvern, UK).
DLS measures the average diameter of a spherical particle through Brownian motion,
where large particles move slower than smaller particles. The resulting light intensity
fluctuations are measured when exposed to a colloidal system (Figure 2.3a).24 Zeta
potential is a measure of the charge of a nanoparticle surface, and is an indication of
colloidal system stability and aggregation potential (Figure 2.3b). The larger the
magnitude of the zeta potential, the greater the repulsive force within the system and
therefore a smaller probability of particulate aggregation.25 For analysis, three replicates
of five different nanoparticle samples were analyzed both for nanoparticle size and zeta
potential. Nanoparticles were suspended in ddH2O and diluted 1:100 to fall into an
appropriate range for the instrument.
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Figure 2.3: (a) Nanoparticle size determination via DLS, where resulting light intensity
fluctuations are used to determine nanoparticle size. (b) Nanoparticle surface charge
determination via zeta potential provides information regarding colloidal repulsion and
aggregation.
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2.3.4 Nitric Oxide Release Quantitation from Nanoparticles
NO release from SNC modified nanoparticles was monitored using the Griess
assay, purchased as a kit from Cayman Chemical.17, 26 The total concentration of NO
released by a system is first measured through the conversion of NO3- to NO2- by nitrate
reductase.27 This conversion is followed by the addition of the Griess reagents, which
converts NO2- into a colored azo compound (Figure 2.4).27 The absorbance of this
chromophore directly determines the concentration of NO2-, as it was converted from
NO.27
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+
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NH2

NH2

N
N

+
SO 2 NH2

SO 2 NH2

N-(1-Naphthyl) ethylenediamine
(Griess Reagent 2)

Azo Product

Figure 2.4: The quantitation of NO via the Griess Assay where the conversion from
nitrate to nitrite (1) followed by reaction with the Griess reagents (2) forms a measurable
chromophoric compound.
NO release from nanoparticles was monitored over 48 hours. Briefly, 5 mg
samples of nanoparticles were suspended in 1 mL PBS and placed on an incubator/shaker
at 37°C, while protected from light. The addition of PBS begins the decomposition
process of RSNOs so that the amount of NO released can be determined.28 At each time
point, aliquots of the PBS supernatant were collected and frozen at -20°C until assay
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preparation. The same volume of PBS that was removed at each time point was
replaced.26
The PBS supernatant samples were thawed and a 96-well plate was prepared per
kit instructions. The assay included reagents that allowed for the construction of a
nitrate/nitrite calibration curve. Briefly, 80 µL of sample was incubated with 10 µL of
enzyme cofactor mixture and 10 µL of nitrate reductase mixture. After a 1-hour
incubation, 50 µL of Griess Reagent R1 and 50 µL of Griess Reagent R2 were added to
each well. The contents of the well were incubated at room temperature for 10 minutes
before UV-Vis analysis. The 96-well plate was read using an Infinite M1000 microplate
reader (Tecan, USA) at an absorbance of 540 nm. The concentration of NO was
determined by information obtained by the calibration curve and equation provided by
Cayman Chemical.27

2.3.5 Antimicrobial Effects of S-Nitrosothiol Modified Nanoparticles
2.3.5.1

Escherichia coli and Staphylococcus epidermidis Culture

2.3.5.1.1 Escherichia coli Culture
E. coli (ATCC® 25922) was frozen in vials of glycerol and stored at -80°C until
use. To begin a culture, one full inoculation loop of E. coli was added to 10 mL of LB
media in a T-25 cm2 culture flask. The E. coli flask was incubated overnight under
shaking conditions at 37°C and diluted to an optical density at 600 nm (OD600nm) of 0.1
before beginning bacterial assays.
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2.3.5.1.2 Staphylococcus epidermidis Culture
S. epidermidis (ATCC® 14990) was frozen in vials of glycerol and stored at
-80°C until use. To begin a culture, one full inoculation loop of S. epidermidis was added
to 10 mL of TSB media in a T-25 cm2 culture flask. The S. epidermidis was incubated
overnight on a shaker incubator at 37°C and diluted to an OD600nm of 0.1 before
beginning bacterial assays.

2.3.5.2

Bacterial Turbidity Tests with Nanoparticles

An analysis based on bacterial optical density was used to monitor the
effectiveness of NO release against planktonic cultures of E. coli in LB media. The
resulting overnight culture of E. coli was diluted to an OD600nm of 0.1 in LB media. SNC
or S-nitroso-penicillamine nanoparticles were prepared at 10 mg/mL in PBS and
unmodified nanoparticles were prepared as a control. To reduce colloidal interferences in
the quantitation of the turbidity, a sterile 0.4 µm filter cell culture insert (Falcon, USA)
was placed in each well and the 10 mg/mL nanoparticle suspension was placed inside the
well insert. In this way, nanoparticles remained in the insert while the NO released by the
nanoparticles could pass through the filter into the cell culture below. In each well of a
24-well plate, 900 µL of the planktonic OD600nm E. coli culture was added. Six wells each
contained: (i) E. coli + PBS, (ii) E. coli + unmodified nanoparticles, or (iii) E. coli +
SNC/S-nitroso-penicillamine modified nanoparticles. The plate was placed in a shaker at
37°C for 3 hours while protected from light. After incubation, the cell culture inserts with
nanoparticles were discarded and the OD600nm was collected for each well using an
Infinite M1000 PRO microplate reader, with unmodified LB media subtracted from each
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well as the blank (n=6). Bacterial turbidity experiments involving S-nitroso-penicillamine
modified nanoparticles were collected using a Varian UV-Vis spectrophotometer.

2.3.5.3

Antibiotic Susceptibility Tests with Nanoparticles

2.3.5.3.1 Determination of Effective Antibiotic Concentration
A commonly prescribed antibiotic for E. coli infections, tetracycline, was chosen
to test the synergistic effect of SNC nanoparticles.29,

30

Vancomycin, an antibiotic

effective against gram-positive Staphylococci, was chosen for antibiotic susceptibility
tests involving S. epidermidis.6, 31 To individual wells on a 48 well plate, concentrations
of 500, 100, 50, 10, 1, 0.1, 0.05, and 0.01 µg/mL of tetracycline or vancomycin was
added to 100 µL of E. coli or S. epidermidis and was diluted to a final volume of 200 µL
with PBS (6 wells each, n=6). The plate was incubated at 37°C under shaking conditions,
and the OD600nm was monitored each hour for 5 hours on the Infinite M1000 PRO
microplate reader. A blank containing LB and the antibiotic was subtracted from each
well. An antibiotic concentration that exhibits some inhibitory effect and is not
completely inhibitory is necessary for this experiment.

2.3.5.3.2 Antibiotic Susceptibility Test with Nanoparticles
The initial E. coli and S. epidermidis culture was grown overnight and diluted to
0.1 OD600nm as described previously. Unmodified and SNC/S-nitroso-penicillamine
nanoparticles were prepared to a concentration of 10 mg/mL in PBS. As with the
bacterial turbidity assay, a sterile 0.4 µm cell culture insert was placed in each well and
the nanoparticle suspension was placed above the filter in the insert. To each of six wells,
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900 µL of planktonic E. coli or S. epidermidis solution was placed in each well of a 24well plate, with: (i) E. coli/S. epidermidis + 100 µL PBS (ii) E. coli/S. epidermidis + 100
µL tetracycline/vancomycin (iii) E. coli/S. epidermidis + 100 µL tetracycline/vancomycin
+

unmodified

nanoparticles

or

(iv)

E.

coli/S.

epidermidis

+

100

µL

tetracycline/vancomycin + SNC/S-nitroso-penicillamine modified nanoparticles. The
plate was incubated for 3 hours at 37°C under shaking conditions. The filter units were
removed before analysis on the plate reader or UV-Vis at 600 nm (n=6).

2.3.6 Cytotoxicity of Nanoparticles
The cytotoxicity of the SNC nanoparticles was determined using 3T3 Swiss
Albino mouse embryo fibroblasts. The cells were maintained in DMEM that was
supplemented with 10% FBS and 1% penicillin/streptavidin. The fibroblasts were
cultured until approximately 80% confluent and cells were removed from the flask by
trypsinization. The suspended cells were diluted to a concentration of 10,000 cells per
mL of fresh DMEM. Cut microscope slides were sterilized using 200-proof ethanol and
UV light and were placed in each well of a 24 well plate and 1 mL of cell suspension was
added to each well. The plate was incubated for 24 hours at 37°C in a 5% carbon dioxide
environment. After 24 hours, the DMEM media was removed and replaced with 1 mL of
fresh media. Cell culture inserts were added to each well and a 10 mg/mL suspension
containing either SNC or unmodified nanoparticles in PBS was added to each well. PBS
was added to each filter unit for control fibroblast samples.
After an additional 24 hour incubation, the number of live and dead fibroblast
cells was determined using a Live/Dead® Viability/Cytotoxicity Kit from Invitrogen
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(Figure 2.5). With this cytotoxicity kit, live cells fluoresce green, while dead cells
fluoresce red. Five spots on each microscope slide with an area of 0.6 mm2 were imaged
under 10x magnification using fluorescence filters on an Axioskop2 with AxioVision
software. The number of live and dead cells was counted on 85 images for each sample
and control. The percent viability for each condition was calculated using Equation 2.1
and normalized to the fibroblast control.
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Figure 2.5: The fluorescent based Live/Dead® Viability/Cytotoxicity assay, where
Calcein AM enters a viable cell, is converted to Calcein by cellular esterase. The Calcien
enters the healthy cell’s nucleus and the cell fluoresces green. Ethidium homodimer
enters a non-viable cell through the membrane, where it binds to DNA in the nucleus, and
causes the cell to fluoresce red.

Equation 2.1: !!!!!!Percent Viability % =

Number of live cells
Number of total cells (live+dead )

2.3.7 Statistics
Statistical analysis was performed using Origin 8.0 software. A one way analysis
of variance (ANOVA) with a Bonferroni post-hoc test was used to determine the
averages and statistical significance of data at the p<0.05 level of significance, where
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applicable. Outliers were determined by the Grubb’s test and excluded from presented
data. All statistically analyzed data is presented as mean ± standard error.

2.4

Results

2.4.1

Nanoparticle Synthesis
DRIFT spectroscopy was used to examine the surface chemistry of the PLGA

nanoparticles (Figure 2.6). The surface of the unmodified nanoparticles included stretches
characteristic of the PVA surfactant with peaks at 3343 cm-1 assigned to vO-H, 2942 cm-1
indicative of the hydrocarbon backbone, 1452 cm-1 assigned to vC-OH, and 1267 cm-1
assigned to vC-O. The peak in the spectrum at 1774 cm-1 can be attributed to the
carboxylic acid groups within the PLGA core. Although many of these stretches overlap
for PLGA and PVA, the broadness of vO-H indicates that the PVA surfactant dominates
the nanoparticle surface with free hydroxyl groups, crucial for further functionalization.5
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Figure 2.6: DRIFT spectrum of unmodified PLGA(a)/PVA(b) nanoparticles, prepared
using a o/w technique. The peak at 3343 cm-1 for vO-H indicates that free hydroxyls are
present on the surface of the nanoparticles, and crucial for further NO functionalization.
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2.4.2 S-Nitrosothiol Immobilization
2.4.2.1

Thin Film Surface Modification

After verification of nanoparticle synthesis, the nanoparticle surface was reacted
with the COOH-Pa, a phosphonic acid, to deposit the organic film onto the surface of the
nanoparticle. The addition of this organic acid presents a more reactive tail group, a
carboxylic acid, at the nanoparticle surface.
The CH2 stretching region of the DRIFT spectrum contains two peaks
corresponding to the asymmetric and symmetric CH2 stretches, at 2913 and 2847 cm-1,
respectively. When compared to COOH-Pa solid, these stretches confirm the presence of
COOH-Pa on the nanoparticle surface (Figure 2.7a). Additionally, these peaks were not
present initially in the DRIFT spectrum of the unmodified nanoparticles. The peak
positions are indicative of a well-ordered film on the nanoparticle surface, characterized
by alkyl chains in an all trans, crystalline-like conformation.8, 32
It has been shown that when using organic acids with both carboxylic and
phosphonic acid functional groups present at both termini, the thin film forms by utilizing
the phosphonic acid as the head group, leaving the carboxylic acid group free at the
nanoparticle surface for further reactions.6, 8, 33 The binding mode of COOH-Pa to the
nanoparticle surface was also examined using DRIFT, where the solid COOH-Pa infrared
spectrum is compared to that of the COOH-Pa modified nanoparticles (Figure 2.7b).6 The
solid COOH-Pa spectrum contains peaks at 1214, 1077, 1008, 951, and 934 cm-1
corresponding to the vP=O, vP-O, asym, vP-O sym, vP-OH, and vP-OH of the phosphonic acid head
group, respectively. The DRIFT spectrum of COOH-Pa bound to the nanoparticle surface
contains one broad peak at 1023 cm-1 for vP-O, combined with the loss of both vP-OH peaks
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and the vP=O peak suggesting a tridentate binding mode. Here, all three oxygen atoms of
the phosphonic acid head group is bound to the nanoparticle surface.6
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Figure 2.7: DRIFT spectra of the methylene stretching region of COOH-Pa on the
nanoparticle surface (a) and the broad peak at 1023 cm-1 in the spectrum of the binding
region of COOH-Pa confirms tridentate binding (b).

2.4.2.2

S-Nitrosocysteamine Modified Nanoparticles: Attachment

The immobilization of SNC was completed through amide bond formation using
traditional carbodiimide coupling. The carboxylic acid group from the COOH-Pa thin
film was first activated with EDC and NHS. The EDC and NHS act to generate a
succinimidyl ester leaving group at the surface that readily reacts with primary amines to
form amide bonds.34 Thus, the carboxylic acid group of COOH-Pa is first activated to a
succinimidyl ester and then reacted with the primary amine within the SNC RSNO donor.
The attachment of SNC to the nanoparticle surface was a “one pot” mixture, in which the
nanoparticles were suspended in a solution containing EDC, NHS, and SNC
simultaneously.21 Successful amide bond formation and presence of the NO group was
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confirmed using DRIFT spectroscopy (Figure 2.8). The appearance of two peaks at 1650
cm-1 for amide I (vC=O of amide) and 1565 cm-1 for amide II (vN-H of amide), both absent
in unmodified nanoparticles, can be attributed to the formation of a secondary amide
bond.6 The attachment of SNC is further confirmed by the appearance of the peak at 1506
cm-1 that is indicative of the N=O stretch of NO and the presence of a peak at 714 cm-1 in
the spectrum that is attributed to vC-S. 22, 23, 35
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Figure 2.8: DRIFT spectrum of the attachment of SNC to the COOH-Pa modified
nanoparticle surface as confirmed by the presence of amide I (1650 cm-1) and amide II
(1565 cm-1), as well as the NO group at 1506 cm-1.
UV-Vis spectroscopy was used in conjunction with DRIFT spectroscopy to
confirm the successful attachment of SNC to the COOH-Pa thin film on the nanoparticle.
Absorbance maxima at 334 nm and at 547 nm are indicative of electronic transitions of π
→ π* and nN → π*, respectively, for the SNO functionality as observed in pure, unbound
SNC (Figure 2.9).22, 23, 36 The absorbance maximum at 334 nm was observed in the
spectra

of

the

dissolved

SNC

modified

nanoparticles

indicating

successful

immobilization of the NO donor onto the PLGA/PVA nanoparticles. The lack of the
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nitrite and nitrous acid signatures in the original SNC donor and SNC modified
nanoparticles indicates that no excess nitrite was present in the samples, crucial for the
success of the NO release assay and antibacterial experiments.
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Figure 2.9: UV-Visible spectra of SNC modified nanoparticles dissolved in
DCM:Methanol, compared to the pure, unbound SNC donor. The wavelength of
maximum absorbance at 334 nm for both the SNC modified nanoparticles and SNC
liquid confirms successful nanoparticle functionalization.

2.4.2.3

S-Nitroso-Penicillamine Modified Nanoparticles: Attachment

The immobilization of S-nitroso-penicillamine was completed through amide
bond formation using traditional carbodiimide coupling, as with SNC. However, in this
reaction, the EDC and NHS were first reacted with the COOH-Pa modified nanoparticles
to generate a succinimidyl ester leaving group at the surface because of the dual
functionality of the S-nitroso-penicillamine molecule.34 Unlike SNC, S-nitrosopenicillamine contains both a carboxylic acid and an amine functionality in the same
molecule. To avoid unwanted reactions with neighboring molecules, the S-nitroso-
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penicillamine was then reacted with the EDC/NHS activated nanoparticles in a two-step
process. The successful amide bond formation and presence of the NO group was
confirmed using DRIFT spectroscopy (Figure 2.10). The appearance of two peaks at
1651 cm-1 (C=O, amide I) and 1574 (N-H, amide II) cm-1, both absent in unmodified
nanoparticles, can be attributed to the formation of the amide bond.6 The attachment of Snitroso-penicillamine is further confirmed by the appearance of the peak at 1508 cm-1 that
is indicative of the N=O stretch of NO and the unreacted carboxylic acid group of Snitroso-penicillamine at 1748 cm-1.
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Figure 2.10: DRIFT spectrum of the attachment of S-nitroso-penicillamine to the
COOH-PA modified nanoparticle surface as confirmed by the presence of amide I (1651
cm-1) and amide II (1574 cm-1). The NO group is present at 1508 cm-1 and the stretch at
1748 cm-1 indicates free carboxylic acid from S-nitroso-penicillamine.
UV-Vis spectroscopy was used in conjunction with DRIFT spectroscopy to
confirm the successful attachment of S-nitroso-penicillamine to the COOH-Pa thin film
on the nanoparticle. Absorbance maxima at 340 nm and at 595 nm are indicative of
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electronic transitions of π → π* and nN → π*, respectively, for the SNO functionality as
observed in pure, unbound S-nitroso-penicillamine (Figure 2.11).22, 23, 36 The absorbance
maximum at 342 nm was observed in the spectra of the dissolved S-nitroso-penicillamine
modified nanoparticles indicating successful immobilization of the NO donor onto the
PLGA/PVA nanoparticles. The functionalization of the nanoparticle surface with Snitroso-penicillamine was less successful than that of the SNC donor, as seen by the
spectral signatures around 350 nm. A significant amount of nanoparticles were dissolved
to a collect a usable spectrum for the modification of nanoparticles with S-nitrosopenicillamine. Thus, these nanoparticles were not characterized to the extent of the SNC
nanoparticles and tested only against E. coli as a comparison in further experiments.
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Figure 2.11: UV-Visible spectra of S-nitroso-penicillamine modified nanoparticles
dissolved in DCM:Methanol, compared to S-nitroso-penicillamine liquid. The
wavelength of maximum absorbance at 342 and 340 nm for both the S-nitrosopenicillamine modified nanoparticles and S-nitroso-penicillamine liquid, respectively,
confirms successful nanoparticle functionalization.
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2.4.3 S-Nitrosocysteamine Modified Nanoparticles: Characterization
Nanoparticle morphology and size was determined using SEM and DLS,
respectively. Based on DLS, a heterogeneous size population was determined for
unmodified nanoparticles while a monodisperse population for SNC modified
nanoparticles. The average nanoparticle size for unmodified nanoparticles was 426.8 ±
11.7 nm with a PDI of 0.210 ± 0.008 (Figure 2.12a) while surface functionalization
increased nanoparticle size to 586.2 ± 14.3 nm (Figure 2.12a). The PDI of the SNC
functionalized nanoparticles was 0.199 ± 0.012. This change in PDI is likely due to the
loss of free hydroxyl groups at the nanoparticle surface, reducing the possibility of
agglomeration. The same trend was also observed using SEM analysis, where
nanoparticle size appears to increase after functionalization (Figure 2.12b). However, the
nanoparticles appear to remain spherical after surface functionalization.
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Figure 2.12: Nanoparticle size of unmodified and unmodified nanoparticles as
determined by DLS (a) with corresponding SEM micrographs (b).
Zeta potential was used to characterize the charge on the surface of both
unmodified and SNC modified nanoparticles. The average zeta potential for unmodified
and SNC nanoparticles was -20.9 ± 0.3 mV and -16.7 ± 0.4 mV, respectively (Figure
2.13). The shift in zeta potential after SNC modification of the nanoparticles is likely due
to the formation of amide bonds at the COOH-Pa tail, indicating that the nanoparticle
surface was successfully functionalized.17, 37, 38
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Figure 2.13: Zeta potential was determined using the Malvern Zetasizer, and indicates
the charge on the nanoparticle surface. The slight shift towards a more positive zeta
potential confirms functionalization of the nanoparticle surface.

2.4.4 S-Nitrosocysteamine Modified Nanoparticles: Nitric Oxide Release
The total amount of NO released per milligram of nanoparticles was determined
using a nitrate/nitrite colorimetric assay (Griess Assay). NO degrades rapidly into nitrate
under physiological conditions and thus in this assay, nitrates were converted to nitrites,
and the total amount of nitrite was quantified. The total amount of NO, reflected from
total nitrite, released by the nanoparticles cumulatively over a 48-hour time period was
37.1 ± 1.1 nmol/mg of nanoparticles (Figure 2.14). The NO was burst released between
the first and second hour of the assay, followed by a slow release of NO for the remainder
of the assay. The maximum amount of NO released, 26.5 ± 1.0 nmol/mg, occurred at the
two-hour time point.
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Figure 2.14: Quantitation of NO release from SNC modified nanoparticles, determined
using the colorimetric nitrate/nitrite Griess assay. The SNC modified nanoparticles
released 37.1 ± 1.1 nmol NO/mg nanoparticles over a 48-hour time period. Each data
point expresses the average NO release ± standard error (n=3).

2.4.5 Bacterial Turbidity Tests with Nanoparticles
2.4.5.1

S-Nitrosocysteamine Modified Nanoparticles

The antibacterial activity of SNC modified nanoparticles was assessed by a
bacterial turbidity E. coli challenge, where the planktonic growth of E. coli incubated
with nanoparticles was monitored. The ability of the SNC NO donor to retain it’s
antimicrobial ability after covalent attachment to the COOH-P thin film is important for
localized, site specific treatment.10 Previous work suggested that nanoparticles added
directly to the E. coli culture interfered with OD600nm measurements; therefore, filter cell
culture inserts were added to each well to avoid nanoparticle dispersion into solution. The
filter insert allowed NO to diffuse into the E. coli culture below without the dispersion of
the nanoparticles. After incubating a 0.1 OD600nm E. coli culture with the nanoparticles
for 3 hours, the OD600nm was collected for all E. coli controls and samples. The
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normalized average OD600nm was 1.00 ± 0.02 for the E. coli control, 1.02 ± 0.08 for the
unmodified nanoparticle control, and 0.681 ± 0.01 for the SNC modified nanoparticles
(Figure 2.15). The OD600nm of the E. coli incubated with 10 mg/mL SNC modified
nanoparticles was statistically lower than both the E. coli control and E. coli treated with
unmodified nanoparticles. E. coli growth in the presence of SNC modified nanoparticles
resulted in a 31.8 ± 0.7 % growth reduction compared to the E. coli control. This
confirms that SNC is active after being immobilized to the nanoparticle surface.
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Figure 2.15: Bacterial turbidity assay of E. coli cultures treated with 10 mg/mL SNC
modified nanoparticles shown as mean ± standard error, p<0.05. E. coli and E. coli
treated with unmodified nanoparticles were not statistically different (#). E. coli
inhibition by SNC modified nanoparticles is statistically different (*) than all other
groups.

2.4.5.2

S-Nitroso-Penicillamine Modified Nanoparticles

The antimicrobial effect of the S-nitroso-penicillamine modified nanoparticles
against E. coli was determined through a bacterial turbidity assay. After incubating a 0.1
OD600nm E. coli culture with the nanoparticles for 2.5 hours, the OD600nm was collected
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for all nanoparticle samples and E. coli controls. The average OD600nm was 1.00 ± 0.01
for the E. coli control, 0.992 ± 0.02 for the unmodified nanoparticle control, and 0.864 ±
0.01 for the S-nitroso-penicillamine modified nanoparticles (Figure 2.16). The OD600nm of
the E. coli incubated with 10 mg/mL S-nitroso-penicillamine modified nanoparticles was
statistically lower than both the E. coli control and E. coli treated with unmodified
nanoparticles. E. coli growth in the presence of SNC modified nanoparticles resulted in a
13.3 ± 2.6 % growth reduction compared to the E. coli control. As confirmed by DRIFT
and UV-Vis spectroscopy, these nanoparticles likely release less NO because of nonoptimized attachment conditions and are therefore less antimicrobial.
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Figure 2.16: Bacterial turbidity assay of E. coli cultures treated with 10 mg/mL Snitroso-penicillamine modified nanoparticles shown as mean ± standard error, p<0.05. E.
coli and E. coli treated with unmodified nanoparticles were not statistically different (#).
E. coli inhibition by S-nitroso-penicillamine modified nanoparticles is statistically
different (*) than all other groups.

54

2.4.6 Antibiotic Susceptibility Tests with Nanoparticles
2.4.6.1

S-nitrosocysteamine Nanoparticles and Escherichia coli

The synergistic effect of an antibiotic with a low concentration of NO was tested
with tetracycline, as it is an effective antimicrobial against gram-negative bacteria. The
concentration of tetracycline used was 100 ng/mL, as determined by testing various
concentrations of tetracycline against E. coli (Figure 2.17). This concentration only
reduced bacterial growth but is not considered fully inhibitory against E. coli.29
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Figure 2.17: (a) Concentrations of tetracycline tested against E. coli to determine an
appropriate concentration to test for the synergistic effect with SNC modified
nanoparticles. The desired concentration should be slightly inhibitory as to still promote
the growth of E. coli. (b) 100 ng/mL tetracycline was selected as the concentration to be
utilized in antibiotic susceptibility assays.
After three hours, the normalized average OD600nm for E. coli without tetracycline
was 1.00 ± 0.03, E. coli treated with 100 ng/mL tetracycline had an OD600nm of 0.738 ±
0.07, the average OD600nm for E. coli in the presence of unmodified nanoparticles and
tetracycline was 0.517 ± 0.09, and the average OD600nm for E. coli cultures in the
presence of SNC modified nanoparticles and tetracycline was 0.0836 ± 0.02 (Figure
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2.18). The OD600nm of E. coli incubated with 10 mg/mL SNC modified nanoparticles and
tetracycline was statistically lower than the E. coli controls and E. coli treated with
unmodified nanoparticles, indicating successful bacterial inhibition. The addition of SNC
nanoparticles to an antibiotic increases the effectiveness of tetracycline by 87.8 ± 3.3 %.
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Figure 2.18: Antibiotic susceptibility challenge in the presence of E. coli cultures treated
with 100 ng/mL tetracycline and 10 mg/mL SNC modified nanoparticles, shown as mean
± standard error, p<0.05. E. coli treated with tetracycline and E. coli treated with
unmodified nanoparticles and tetracycline were not statistically different (#). E. coli
treated with SNC modified nanoparticles and tetracycline is statistically different (*) than
all other groups.

2.4.6.2

S-Nitroso-Penicillamine Modified Nanoparticles and
Escherichia coli

The S-nitroso-penicillamine modified nanoparticles were combined with 100
ng/mL tetracycline to observe the synergistic effect of the NO released from these
nanoparticles with an antibiotic. These nanoparticles exhibited less of an antimicrobial
effect than the SNC modified nanoparticles, and thus it was expected that the S-nitroso-
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penicillamine modified nanoparticles would not show as significant of a synergistic
effect.
After 2.5 hours, the normalized average OD600nm for E. coli without tetracycline
was 1.00 ± 0.02, E. coli treated with 100 ng/mL tetracycline had an OD600nm of 0.466 ±
0.004, the average OD600nm for E. coli in the presence of unmodified nanoparticles and
tetracycline was 0.452 ± 0.006, and the average OD600nm for E. coli cultures in the
presence of S-nitroso-penicillamine modified nanoparticles and tetracycline was 0.404 ±
0.003 (Figure 2.19). The OD600nm of E. coli incubated with 10 mg/mL S-nitrosopenicillamine modified nanoparticles and tetracycline was statistically lower than the E.
coli controls and E. coli treated with unmodified nanoparticles, indicating successful
bacterial inhibition. However, the addition of S-nitroso-penicillamine nanoparticles to
reduces bacterial growth by 13.2 ± 1.5 %, indicating a limited synergistic effect. The
concentration of NO released from the nanoparticle surface is likely too low to exhibit the
desired synergistic effect.
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Figure 2.19: Antibiotic susceptibility challenge in the presence of E. coli cultures treated
with 100 ng/mL tetracycline and 10 mg/mL S-nitroso-penicillamine modified
nanoparticles, p<0.05. E. coli treated with tetracycline and E. coli treated with
unmodified nanoparticles and tetracycline were not statistically different (#). E. coli
treated with S-nitroso-penicillamine modified nanoparticles and tetracycline is
statistically different (*) than all other groups.

2.4.6.3

S-Nitrosocysteamine Modified Nanoparticles and Staphylococcus
epidermidis
The SNC modified nanoparticles when in combination with tetracycline

exhibited a synergistic effect. The same effect was tested with S. epidermidis in the
presence of a gram-positive effective antibiotic, vancomycin. The concentration of
vancomycin used was 5 µg/mL, as determined by testing various concentrations of
vancomycin against S. epidermidis (Figure 2.20). This concentration reduced bacterial
growth slightly but is not considered fully inhibitory against S.epidermidis.29
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Figure 2.20: (a) Concentrations of vancomycin tested against S. epidermidis to determine
an appropriate concentration to test for the synergistic effect with SNC modified
nanoparticles. The desired concentration should be slightly inhibitory as to still promote
the growth of S. epidermidis. (b) 5 µg/mL vancomycin was selected as the concentration
to be utilized in antibiotic susceptibility assays.
After three hours, the normalized average OD600nm for S. epidermidis without
vancomycin was 1.00 ± 0.01, S. epidermidis treated with 5 µg/mL vancomycin had an
OD600nm of 0.742 ± 0.03, the average OD600nm for E. coli in the presence of unmodified
nanoparticles and vancomycin was 0.433 ± 0.01, and the average OD600nm for S.
epidermidis in the presence of SNC modified nanoparticles and vancomycin was 0.372 ±
0.01 (Figure 2.21). The OD600nm of S. epidermidis incubated with 10 mg/mL SNC
modified nanoparticles and vancomycin was not statistically different than the S.
epidermidis cultures treated with unmodified nanoparticles and vancomycin, indicating
no synergistic effect against a gram-positive bacteria species. Additionally, the S.
epidermidis treated with vancomycin control and the S. epidermidis treated with
unmodified nanoparticles and vancomycin were not statistically the same, indicating that
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S. epidermidis are likely adhering the filter units and is removed from the culture,
reducing the OD600nm.
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Figure 2.21: Antibiotic susceptibility challenge in the presence of S. epidermidis cultures
treated with 5 µg/mL vancomycin and 10 mg/mL SNC modified nanoparticles, shown as
mean ± standard error, p<0.05. S. epidermidis treated with SNC modified nanoparticles
and vancomycin and S. epidermidis treated with unmodified nanoparticles and
vancomycin were not statistically different (#), indicating no synergistic effect. The
vancomycin controls were statistically different (*), indicating that S. epidermidis cells
were likely adhering to the filter unit.
Due to lack of a synergistic effect with a gram-positive bacterium, vancomycin,
and SNC modified nanoparticles, a 0.1 OD600nm culture of S. epidermidis was treated with
100 µM of unbound, pure SNC. The resulting OD600nm for the S. epidermidis control was
1.00 ± 0.01 and 0.785 ± 0.02 for S. epidermidis treated with the SNC donor (Figure 2.22).
The SNC liquid treated S. epidermidis is statistically different from the S. epidermidis
control, but even at µM concentrations, SNC is not very antimicrobial against this grampositive bacterium. Thus, nM concentrations of NO released from the SNC nanoparticles
would not inhibit S. epidermidis growth.
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Figure 2.22: Bacterial turbidity assay of S. epidermidis cultures treated with 100 µM
SNC liquid shown as mean ± standard error, p<0.05. S. epidermidis and S. epidermidis
treated SNC were statistically different (*), indicating some inhibition.

2.4.7 Cytotoxicity of Nanoparticles
The cell viability of NIH3T3 fibroblasts treated with SNC nanoparticles was
determined by the Live/Dead® Viability/Cytotoxicity Assay. Live and dead cells were
counted on each microscope image and the average percent viability was calculated.39
The resulting data was normalized to the fibroblasts treated with PBS. The normalized
average percent cell viability for fibroblasts grown in the presence of PBS, unmodified
nanoparticles, and SNC modified nanoparticles was 100.0 ± 2.2 %, 103.2 ± 2.2 %, and
100.8 ± 3.7 %, respectively (Figure 2.23). Fibroblasts treated with SNC nanoparticles had
statistically the same percent cell viability as both controls, indicating that
functionalization of the surface to release NO did not cause the nanoparticles to be
cytotoxic to mammalian cells.
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Figure 2.23: Normalized average percent cell viability of NIH3T3 mouse embryo
fibroblasts grown in the presence of PBS, unmodified nanoparticles, and SNC modified
nanoparticles. Data is shown as mean ± standard error, p<0.05. Fibroblast growth was not
statistically different between controls and nanoparticle samples. The Live/Dead images
of the NIH3T3 fibroblasts are below, from left to right: fibroblast control, fibroblasts
treated with unmodified nanoparticles, and fibroblasts treated with SNC modified
nanoparticles.

2.5

Discussion
RSNO donors have been previously incorporated into silica particles40 but have

not been immobilized on polymer nanoparticles using thin film modification techniques.
Additionally, most work involving nanoparticles utilizes potentially carcinogenic Ndiazeniumdiolate chemistry.13-16,

41, 42

Here, we investigated the release of NO from

functionalized PLGA nanoparticles to reduce E. coli growth and increase the
effectiveness of an antibiotic, as NO has been shown to be an effective antimicrobial
62

agent against planktonic and biofilm bacterial growth. These polymer nanoparticles have
the potential to be delivered via aerosol methods to the lungs, especially in patients with
CF, where bacterial biofilms can have detrimental effects.
The nanoparticle surface was first modified with a COOH-Pa thin film. The
phosphonic acid head group of the organic acid was successfully bound to the
nanoparticle surface using the free hydroxyl groups present on the nanoparticle surface
from the PVA surfactant. The CH2 stretches within the DRIFT spectrum indicate that the
COOH-Pa molecules presented on the surface are alkyl-chain ordered, giving optimal,
crystalline packing of these molecules on the surface (Figure 2.7a). COOH-Pa was bound
to the surface in a tridentate manner with all three oxygen atoms bound to the
nanoparticle (Figure 2.7b).6
The free carboxylic acid tails, as well as any accessible carboxylic acid groups
from the PLGA nanoparticle core, are available for carbodiimide coupling with the
primary amine functionality within SNC and S-nitroso-penicillamine. The appearance of
two stretches indicative of amide I and amide II bond formation in the infrared spectra
indicate successful SNC (Figure 2.8) and S-nitroso-penicillamine (Figure 2.10)
attachment to the surface. Additionally, the NO moiety appears in the infrared spectra,
further verifying the presence of SNC and S-nitroso-penicillamine on the nanoparticle
surface.
Attachment was also confirmed using UV-Vis spectroscopy. The SNC and Snitroso-penicillamine modified nanoparticles dissolved in DCM:methanol had the same
spectral signature as pure, unbound SNC (Figure 2.9) and S-nitroso-penicillamine (Figure
2.11). Unfortunately, there appears to be less NO on the surface of S-nitroso-
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penicillamine modified nanoparticles, because a higher concentration of nanoparticles
were required to obtain an interpretable UV-Vis spectrum. With this higher concentration
of particles, interferences from the PLGA and PVA are present around 350 nm. Due to
the two-step preparation process of the S-nitroso-penicillamine nanoparticles, it was
likely that optimal activation of the carboxylic acid tail of COOH-Pa was not achieved,
ultimately leading to less S-nitroso-penicillamine attachment. Thus, these S-nitrosopenicillamine nanoparticles were not characterized further, and used only for a
comparison of antimicrobial activity.
Overall, the spectra of both the unbound liquid SNC and SNC modified
nanoparticles lack contributions from excess nitrite and nitrous acid from the synthesis
step,43 allowing for NO quantification using the Griess assay17. From this assay, it was
determined that 37.1 ± 1.1 nmol of NO was released per mg of SNC nanoparticles,
similar to what has been reported in other RSNO modified nanoparticles (Figure 2.14).17
The carboxylic acid groups within the PLGA core of the nanoparticles may have been
nitrosylated, allowing for the extended release of NO over the 48 hours of the assay.
There was a change in both nanoparticle size and zeta potential after modification
of the nanoparticles with SNC, indicating successful modification (Figure 2.12). The size
of the SNC modified nanoparticles is larger than the unmodified nanoparticles, since
another layer is added when the nanoparticles are modified with COOH-Pa and SNC,
which is consistent with previous work by Sperling et al. and Pellegrino et al.44, 45 The
developed SNC modified nanoparticles are larger than other NO delivering nanoparticle
systems, such as silicon and gold.14,

15, 17, 46

but other systems are not made of

biodegradable polymers suitable for biomedical applications. However, the size of the
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nanoparticles is still at a size that could be utilized for inhalation drug delivery.47, 48 The
zeta potential of the SNC modified nanoparticles shifts slightly more positive, likely due
to the reduction of the free hydroxyl groups present on the nanoparticle surface (Figure
2.13). However, the zeta potential remains negative overall, an indication of the
electrophilic molecule S-nitrosation at the surface.17
The nanomolar amount of NO released from the SNC nanoparticles has a
bacteriostatic effect on E. coli cultures, as observed from the bacterial turbidity assay and
antibiotic susceptibility challenge. E. coli growth was inhibited 31.8 ± 0.7 % when
treated with 10 mg/mL SNC nanoparticles, which is significantly different than controls
(p<0.05) (Figure 2.15). The S-nitroso-penicillamine modified nanoparticles inhibited E.
coli growth by 13.2 ± 1.5 %, which is significantly different from the other E. coli
controls (p<0.05), but is not as bacteriostatic as the SNC modified nanoparticles (Figure
2.16). This further confirms the results obtained by the UV-Vis spectroscopy, as there is
likely less NO on the surface of the S-nitroso-penicillamine modified nanoparticles.
A synergistic effect of NO and an antibiotic against P. aeruginosa was observed
by Barraud et al.29 In this antibiotic susceptibility assay, a small concentration of the
antibiotic tobramycin and a nM amount of sodium nitroprusside were incubated with
planktonic cultures of P. areuginosa.29 The resulting bacterial culture showed a 2-log
decrease in growth (via a colony forming units assay) compared to just the antibiotic
alone, indicating that NO increased the effectiveness of an antibiotic.29 The SNC
nanoparticles developed here offered a synergistic effect against E. coli when coupled
with 100 ng/mL tetracycline, resulting in a 87.8 ± 3.3 % reduction in growth when
compared to E. coli cultures treated only with tetracycline (p<0.05) (Figure 2.18). This is
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advantageous because these nanoparticles are capable of increasing the effectiveness of
antibiotics, thus less antibiotic would be needed to treat a bacterial infection and
subsequently reduce the risk of antibiotic bacterial resistance. NO is thought to change
the physiology of bacterial cells, making them more susceptible to antibiotics.29 The Snitroso-penicillamine exhibited only a bacteriostatic effect against E. coli and did not
significantly increase the effectiveness of tetracycline (Figure 2.19). This was likely due
to the limited attachment of S-nitroso-penicillamine to the nanoparticles, where less NO
is released from the surface.
Unfortunately, the SNC modified nanoparticles when coupled with vancomycin
did not exhibit a synergistic effect against S. epidermidis (Figure 2.20). A larger
concentration of NO delivered from 100 µM of liquid SNC showed limited bacterial
inhibition of S. epidermidis (Figure 2.21), indicating that the amount of NO being
released from the nanoparticles was not enough to reduce bacterial growth. Grampositive bacteria are capable of producing their own NO through bacterial NOS and as
shown by Gusarov et al., NO production in a gram-positive bacterial cell increases as
bacterial cells are subjected to an antibiotic.49 Thus, the endogenously delivered nM
amounts of NO in the presence of vancomycin does not inhibit bacterial growth because
the bacteria in the population are already making their own NO.49
To consider these nanoparticles as a NO delivery vehicle in vivo, they should not
elicit cytotoxic effects against mammalian cells in vitro. Though the SNC modified
nanoparticles inhibit bacterial cells, they should not inhibit NIH3T3 fibroblast growth.
The SNC modified nanoparticles showed no cytotoxic effect to fibroblasts after 24 hours,
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as the percent viability of fibroblasts treated with SNC nanoparticles, unmodified
nanoparticles, and PBS were all statistically the same (p<0.05) (Figure 2.22).

2.6

Conclusions
PLGA nanoparticles with PVA surfactant were developed using a o/w emulsion

technique, in which the PLGA was encapsulated on the interior of the nanoparticles and
the PVA presented hydroxyl groups on the exterior of the nanoparticle. The hydroxyl
groups were reacted with an organic acid to form a functional thin film on the
nanoparticle surface. The organic acid presented a more reactive carboxylic acid
functional group at the surface, allowing for amide bond formation between two RSNO
NO donors containing a primary amine: S-nitrosocysteamine and S-nitroso-penicillamine
(Figure 2.24).
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Figure 2.24: PLGA/PVA nanoparticles were modified with a phosphonic acid thin film
and then functionalized at the tail group to immobilize (a) SNC or (b) S-nitrosopenicillamine.
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DRIFT and UV-Vis analysis was used to confirm RSNO attachment to the
nanoparticle surface and DLS, SEM, and zeta potential was utilized to characterize size,
morphology, and zeta potential, respectively, of the functionalized nanoparticles. The
nanoparticles released nM amounts of NO in vitro and were bacteriostatic against E. coli
cultures, while increasing the effectiveness of an antibiotic. The low concentration of NO
released from the nanoparticle surface was not enough to inhibit S. epidermidis growth,
as Staphylococci species are capable of producing their own NO. These nanoparticles
were non-cytotoxic to mammalian cells and offer the potential deliver NO directly to an
infection site (i.e. bacterial growth in the lungs), while reducing the amount of antibiotic
needed, limiting the possibility of antibiotic resistance.
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Chapter 3: Functionalization, Characterization, and Antimicrobial
Activity of Nitric Oxide Releasing Titanium-Aluminum-Vanadium
Alloy
3.1

Introduction
Titanium and its alloys have been utilized as a joint replacement material for

dental, cardiovascular, and structural applications, due to strength of the materials,
biocompatibility and corrosion resistance. Titanium-aluminum-vanadium (Ti-6Al-4V)
alloy was developed as an alternative to commercially pure titanium as it has an increased
elastic modulus, yield strength, and ultimate strength, factors important for the
development of a metallic implant material.1, 2 Additionally, Ti-6Al-4V implant materials
are favored over stainless steel and cobalt-chromium materials because it has a stiffness
closer to that of natural bone, resulting in less stress shielding of bone when implanted.3
The biocompatibility and corrosion resistance of Ti-6Al-4V is due to the thin, but
strongly adhered oxide layer that instantaneously occurs after the alloy is exposed to
oxygen or water.4, 5 This oxide coating serves as a protective layer against the attack of
corrosive forces, such as biological proteins, salts, water, and oxygen.5, 6
Ti-6Al-4V implant materials are utilized in hip joint and knee joints, where hard
tissue has failed.3 In these applications, tissue regeneration and osseointegration is
important to reduce implant wear, rejection, and failure.2, 7 Implant rejection and failure
can also result from infection.3,

8, 9

If bacterial adhesion occurs before the tissue

regeneration process takes place after implantation, the host defense cannot prevent the
surface colonization of bacteria, potentially leading to biofilm formation and infection.3
Thus, inhibiting initial bacterial adhesion through anti-infective implant materials would
be essential to preventing implant failure and rejection.3 Antimicrobial compounds, such
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as antibiotics,10-13 metal ions,14 and antimicrobial peptides,15, 16 have been presented at the
surface of metal and ceramic biomaterials using synthetic and natural polymeric coatings,
physisorption, and SAMs to reduce bacterial adhesion and colonization. Gao and
coworkers developed a hydrophilic siloxane polymer coating on the surface of Ti-6Al-4V
that chemically cross-linked various antimicrobial peptides to reduce bacterial adhesion.17
Others have utilized naturally antimicrobial polymeric coatings, such as chitosan and
fibronectin, to reduce bacterial adhesion to implant materials.18-20 The presentation of
antimicrobial metal ions, such as copper, silver, and zinc, at the implant surface can also
reduce bacterial adhesion by damaging a bacterial cell membrane upon contact.21 These
metal ions have also been incorporated into polymeric coatings at the surface of the
implant material.22 These aforementioned approaches chemically alter the outermost
layer of the metallic biomaterial while preserving the physical properties of the implanted
metal material below.23
SAMs are ordered molecular assemblies that form spontaneously via
chemisorption onto an oxide rich material and are composed of a head group, alkyl chain,
and a tail group.24, 25 Monolayer formation begins when the head group of an individual
molecule binds to the oxide rich layer of a metal or metal alloy surface (Figure 3.1a).25
Formation and growth of a monolayer occurs when additional organic acid molecules
react with the surface, aggregate into islands, and islands coalesce over time while the
alkyl chains align to form an ordered film of molecules (Figure 3.1b).24, 26, 27
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Figure 3.1: SAM molecule interacting with the metal oxide surface (a) and growth of a
SAM via island formation and aggregation.
The choice of head group is crucial for SAM stability and those formed from
aliphatic molecules containing a phosphonic acid head group adhere more strongly to
metal alloy oxide surfaces than molecules containing a carboxylic acid, sulfonic acid, or
hydroxamic acid.25 The long aliphatic alkyl chains of SAMs promote order and further
stabilization through van der Waals interactions within the carbon chain backbone.25, 28-31
Ordered films that contain alkyl chains with greater than twelve carbons typically adopt
an all trans configuration, and are considered crystalline in structure (Figure 3.2a). Alkyl
chains with less than twelve carbons typically form disordered monolayers on the metal
oxide surface and present a liquid-like structure with gauche interactions. These
interactions minimize the amount of van der Waals forces that occur between the
neighboring carbon chains (Figure 3.2b).31, 32 The SAM can be further stabilized through
hydrogen bonding interactions between the tail groups of neighboring molecules within
the SAM.33 These tail groups ultimately control the interfacial properties at the surface
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and can be utilized for further surface reactions, such as through the immobilization of
bioactive molecules. 2, 10-12, 16, 34

Metal Oxide

Metal Oxide

Bulk Metal

Bulk Metal

(a)

(b)

Figure 3.2: (a) SAMs can form in an ordered, crystalline all trans configuration
monolayer or (b) in a disordered liquid-like monolayer with gauche interactions.
Functionalizing the surface of Ti-6Al-4V metal implant materials has the
advantage of direct delivery of antimicrobial compounds to a potential infection site,
specifically the site of surgical implantation. To date, there have been no reports of
covalent immobilization of NO releasing molecules to the surface of Ti-6Al-4V for
antimicrobial applications. Stainless steel 316L and cobalt-chromium metallic implant
materials have been developed to deliver NO through physisorption35 or polymeric
coatings,36, 37 but utilize potentially carcinogenic NONOates in all cases. Here, Ti-6Al-4V
was modified to release NO from a SAM containing a phosphonic acid head group and
carboxylic acid tail group. A reaction at the monolayer terminus provides an interface for
further surface reactions in which a RSNO NO donor could be immobilized onto the
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surface. The functionalized Ti-6Al-4V substrates were tested for antimicrobial properties
and cytotoxic effects.

3.2

Materials
Ti-6Al-4V (composed of 90% titanium, 6% aluminum, and 4% vanadium) foil of

a 0.52 mm thickness was purchased from Goodfellow, Inc. COOH-Pa (97%), NHS, EDC,
D-penicillamine (98-101%), NaNO2 (99.999% trace metal), and Dulbecco’s PBS
(pH=7.4) were purchased from Sigma-Aldrich and used as received. DTPA (>99.0%)
was purchased from Fluka. HCl and 2-propanol (Optima) were obtained from Fisher
Scientific, and used as received. Tetrahydrofuran (THF, Optima) was obtained from
Fisher Scientific and was distilled over sodium and benzophenone before use. Ethanol
(200 proof) and deionized water (ddH2O) were obtained from Duquesne University. The
nitrate/nitrite colorimetric assay kit was purchased from Cayman Chemical Company.
LB Media was obtained from MP Biomedicals, Inc. and two capsules were
dissolved per 50 mL of ddH2O and autoclaved before use. Tetracycline hydrochloride
was obtained from Fisher Scientific. Ampicillin sodium salt was obtained from SigmaAldrich. E. coli (ATCC® 25922), S. epidermidis (ATCC® 14990), 3T3 Swiss Albino
mouse embryo fibroblasts (CCL-92) were obtained from ATCC. DMEM, FBS,
penicillin/streptavidin, and Trypsin/EDTA were purchased from LONZA. The
LIVE/DEAD® Cytotoxicity/Viability Assay Kit for mammalian cells was purchased
from Life Technologies/Fisher Scientific.
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3.3

Methods

3.3.1 Ti-6Al-4V Preparation
Ti-6Al-4V foils were sanded using four decreasing grain size sand papers (150,
320, 400 and 600 grit) and then cut into 1 cm by 1 cm square coupons. The coupons were
cleaned by sonication in acetone for 15-minutes, followed by immersion in boiling
methanol for 15-minutes. This cleaning procedure removes impurities from
manufacturing, organic material, and metallic dust from the surface of the metal coupons.
The coupons were placed in a 60°C oven overnight to dry before further use.

3.3.2 S-Nitroso-Penicillamine Immobilization onto Ti-6Al-4V
S-nitroso-penicillamine, a RSNO NO donor, was immobilized onto the surface of
Ti-6Al-4V metal oxide alloy using a two-step approach (Scheme 3.1). Briefly, SAMs of
COOH-Pa were formed on the oxide surface of Ti-6Al-4V, presenting a carboxylic acid
group at the tail of the formed monolayer. Carbodiimide coupling was utilized to form an
amide bond with the primary amine within the S-nitroso-penicillamine NO donor and the
carboxylic acid functionality at the surface of the Ti-6Al-4V.
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Scheme 3.1: The two-step reaction sequence for the immobilization of S-nitrosopenicillamine to the surface of COOH-Pa modified Ti-6Al-4V. The carboxylic acid group
is first activated with EDC and NHS (1) and then reacted with S-nitroso-penicillamine to
form an amide bond (2).

3.3.2.1

Self-Assembled Monolayer Formation

SAMs of COOH-Pa were formed on the surface of cleaned Ti-6Al-4V using an
aerosol spray deposition method. A 1 mM solution of COOH-Pa was prepared in distilled
THF and was poured into a thin layer chromatography (TLC) sprayer. The TLC sprayer
was used in conjunction with a stream of nitrogen gas to spray the 1 mM COOH-Pa
solution onto the Ti-6Al-4V coupons in four different cycles. Each coupon was sprayed
once with COOH-Pa, placed in the 60°C oven for 30 minutes, and then sprayed again
with COOH-Pa for a total of four cycles. The coupons were then placed in the oven at
60°C overnight to remove excess solvent before film characterization. To test monolayer
stability, the coupons were rinsed and sonicated in THF for 15 minutes to remove any
physisorbed or weakly chemisorbed COOH-Pa molecules.
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3.3.2.2

Activation of COOH-Pa Modified Ti-6Al-4V

Coupons with stable COOH-Pa monolayers were immersed in a solution
containing 20 mM EDC and 50 mM NHS in 2-propanol.10, 38 The reaction proceeded with
nitrogen bubbling through the solution for 1.5 hours, protected from light. The coupons
were removed from solution and dried under vacuum (0.1 Torr) for 45 minutes before
further reaction.

3.3.2.3

S-Nitroso-Penicillamine Immobilization to COOH-Pa Modified
Ti-6Al-4V

S-nitroso-penicillamine was generated by reacting D-penicillamine with acidified
nitrite. Briefly, 100 mM of penicillamine was reacted with 100 mM NaNO2 and 250 mM
HCl in the presence of 100 μM DTPA (a copper chelator) in an ice bath for 1 hour and 15
minutes, while protected from light (Scheme 3.2).39, 40

HS

O
OH
NH2

NaNO2, HCl, DTPA
0oC

ONS

O
OH
NH2

Scheme 3.2: The formation of S-nitroso-penicillamine from the reaction of acidified
nitrite with penicillamine in the presence of a metal chelator.
After RSNO formation, four mL of the S-nitroso-penicillamine solution was
diluted with 6 mL of 200 proof ethanol. The activated COOH-Pa coupons were immersed
in the ethanol solution for 1.5 hours, with nitrogen bubbling through. The coupons were
removed from the solution without a solvent meniscus and placed under vacuum
overnight to dry.
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3.3.3 Characterization of Nitric Oxide Releasing Ti-6Al-4V
3.3.3.1

Infrared Spectroscopy

SAM formation and stability, as well as the activation and immobilization steps of
S-nitroso-penicillamine on Ti-6Al-4V, was characterized using a Nexus 470 Fourier
Transform Infrared (FTIR) spectrometer with a diffuse reflectance infrared Fourier
transform (DRIFT) attachment. Infrared spectroscopy was used to analyze the alkyl chain
ordering and binding modes of monolayers formed and functional groups present at the
surface of Ti-6Al-4V after activation and functionalization of the surface. Each sample
was analyzed under inert conditions with 256 scans (4000 to 400 cm-1) and a 4 cm-1
resolution. Clean, unmodified Ti-6Al-4V was used as a background before sample
collection.

3.3.3.2

Ultraviolet-Visible Spectroscopy

Liquid S-nitroso-penicillamine was scanned from 800 nm to 250 nm using a
Varian UV-Vis spectrophotometer (Agilent Technologies, USA) to determine the
wavelength of maximum absorbance and the purity of the formed RSNO compound. Snitroso-penicillamine was diluted 1:1 with ddH2O to reduce signal saturation.

3.3.4 Nitric Oxide Release Quantitation from Modified Ti-6Al-4V
NO release from S-nitroso-penicillamine modified Ti-6Al-4V was monitored over
48 hours using the Griess assay.35, 41 Briefly, a three coupons of S-nitroso-penicillamine
modified Ti-6Al-4V were added to three separate vials containing 900 μL of PBS and
placed on an incubator/shaker at 37°C, while protected from light. The metal ions
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contained in PBS begins the decomposition process of RSNOs so that the amount of NO
released can be determined.42 At each time point, the PBS was collected and frozen at
-20°C until assay preparation. The same volume of PBS that was removed at each time
point was replaced.35
The PBS samples were thawed and a 96-well plate was prepared per kit
instructions. The assay included reagents that allowed for the construction of a
nitrate/nitrite calibration curve. Briefly, 80 μL of thawed PBS sample was incubated with
10 μL of enzyme cofactor mixture and 10 μL of nitrate reductase mixture. After a 1-hour
incubation, 50 μL of Griess Reagent R1 and 50 μL of Griess Reagent R2 were added to
each well. The well plate was incubated at room temperature for 10 minutes before being
read using an Infinite M1000 microplate reader (Tecan, USA) at an absorbance of 540
nm. The concentration of NO was determined by information obtained by the calibration
curve and equation provided by Cayman Chemical (n=9).43

3.3.5 Antimicrobial Effects of Nitric Oxide Releasing Ti-6Al-4V
3.3.5.1
3.3.5.1.1

Escherichia coli and Staphylococcus epidermidis Culture
Escherichia coli

E. coli (ATCC® 25922) was frozen in vials of glycerol and stored at -80°C until
use. To begin a culture, one full inoculation loop of E. coli was added to 10 mL of LB
media in a T-25 cm2 culture flask. The E. coli flask was incubated overnight under
shaking conditions at 37°C and diluted to an OD600nm of 0.1 before beginning bacterial
assays.
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3.3.5.1.2

Staphylococcus epidermidis

S. epidermidis (ATCC® 14990) was frozen in vials of glycerol and stored at
-80°C until use. To begin a culture, one full inoculation loop of S. epidermidis was added
to 10 mL of LB media in a T-25 cm2 culture flask. LB media promoted slower growth of
S. epidermidis and thus was used over TSB. The S. epidermidis was incubated overnight
on a shaker at 37°C and diluted to an OD600nm of 0.1 before beginning bacterial assays.
Experiments involving S. epidermidis required orbital shaking conditions at 230 RPM to
prevent bacterial cell adhesion to the individual wells of the well plates.

3.3.5.2

Bacterial Turbidity Assay with S-Nitroso-Penicillamine

The antimicrobial effect of the unbound, S-nitroso-penicillamine donor was tested
against both E. coli and S. epidermidis before testing NO release from the Ti-6Al-4V
coupons. In each well of a 24-well plate, 100 μL of diluted S-nitroso-penicillamine (final
well concentration of 5 μM) or PBS and 900 μL of planktonic OD600nm E. coli or S.
epidermidis culture was added. Three wells each contained: (i) E. coli/S. epidermidis +
PBS and (ii) E. coli/S. epidermidis + S-nitroso-penicillamine. The plate was placed in a
shaker incubator (230 rpm for S. epidermidis) at 37°C for 2.5 hours while protected from
light. After incubation, the OD600nm was collected for each well using a Varian UV-Vis
spectrophotometer with three replicates read per well (n=9). LB media containing PBS or
S-nitroso-penicillamine was utilized as the blank.
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3.3.5.3

Bacterial Turbidity Assay with Nitric Oxide Releasing Ti-6Al-4V

Bacterial optical density was used to monitor the effectiveness of NO release from
Ti-6Al-4V coupons against planktonic cultures of E. coli and S. epidermidis in LB media.
In each well of a 24-well plate, 100 μL PBS and 900 μL of planktonic OD600nm E. coli or
S. epidermidis culture was added. Three wells each contained: (i) E. coli/S. epidermidis,
(ii) E. coli/S. epidermidis + unmodified Ti-6Al-4V, or (iii) E. coli/S. epidermidis + Snitroso-penicillamine modified Ti-6Al-4V. The plate was placed in a shaker incubator
(230 rpm for S. epidermidis) at 37°C for 2.5 hours while protected from light. After
incubation, the OD600nm was collected for each well using a Varian UV-Vis
spectrophotometer with three replicates read per well (n=9). LB media containing PBS
was utilized as the blank.

3.3.5.4
3.3.5.4.1

Antibiotic Susceptibility Assay with Nitric Oxide Releasing
Ti-6Al-4V
Determination of Effective Antibiotic Concentration

As previously mentioned, a synergistic effect of nanomolar concentrations of NO
and an antibiotic against P. aeruginosa was observed by Barraud et al.44 Thus, the
synergistic effect of NO release from S-nitroso-penicillamine modified Ti-6Al-4V was
determined. 100 ng/mL tetracycline was found used to only slightly inhibit bacterial
growth, and thus was used in the antibiotic susceptibility assay involving E. coli.
Ampicillin, an antibiotic commonly prescribed for gram-positive bacterial
infections, was tested for synergistic effects with S-nitroso-penicillamine modified Ti6Al-4V against S. epidermidis.45 To individual wells on a 24 well plate, concentrations of
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0.4, 0.5, and 0.6 μg/mL of ampicillin was added to 900 μL of S. epidermidis to reach a
final volume of 1000 μL with PBS (3 wells each). Concentrations greater than 1 μg/mL
were completely inhibitory against S. epidermidis cultures. The plate was incubated at
37°C under shaking conditions, and the OD600nm was determined after 2.5 hours on the
using the Varian UV-Vis spectrophotometer. Each well was read in triplicate with LB
and the concentration of antibiotic subtracted as blank (n=9). An antibiotic concentration
that exhibits a bacteriostatic effect is needed for the antibiotic susceptibility assay.44

3.3.5.4.2

Antibiotic Susceptibility of Nitric Oxide Releasing Ti-6Al-4V

To each of three wells, 900 μL of planktonic E. coli or S. epidermidis culture was
placed in each well of a 24-well plate, with: (i) E. coli/S. epidermidis + 100 μL PBS, (ii)
E. coli/S. epidermidis + 100 μL tetracycline/ampicillin + unmodified Ti-6Al-4V or (iii) E.
coli/S. epidermidis + 100 μL tetracycline/ampicillin + S-nitroso-penicillamine modified
Ti-6Al-4V. The plate was incubated for 2.5 hours at 37°C under shaking conditions (230
rpm for S. epidermidis experiments). The bacterial turbidity of each well was collected
using the Varian UV-Vis spectrophotometer at 600 nm, with 3 replicates of each well and
LB media with the antibiotic/PBS subtracted as the blank (n=9).

3.3.6 Cytotoxicity of Nitric Oxide Releasing Ti-6Al-4V
The cytotoxicity of S-nitroso-penicillamine modified Ti-6Al-4V was determined
using 3T3 Swiss Albino mouse embryo fibroblasts. The cells were maintained in DMEM
that was supplemented with 10% FBS and 1% penicillin/streptavidin. The fibroblasts
were cultured until approximately 80% confluent. The cells were trypsinized from the
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flask, counted, and were diluted to a concentration of 10,000 cells per mL of fresh
DMEM. Three of each type of coupon, either unmodified or S-nitroso-penicillamine
modified Ti-6Al-4V, was placed in a well of a 24 well plate and 1 mL of cell suspension
was added. The plate was incubated for 24 hours at 37°C in a 5% carbon dioxide
environment.
After a 24 hour incubation, the number of live and dead fibroblast cells on the Ti6Al-4V surfaces was determined using a Live/Dead® Viability/Cytotoxicity Kit. Five
spots on each microscope slide with an area of 0.6 mm2 were imaged under 10x
magnification using fluorescence filters on an Axioskop2 with AxioVision software. The
number of live and dead cells was counted on 45 images for each sample and control.
The percent viability for each condition was calculated using Equation 2.1 and
normalized to the fibroblast control.46

3.3.7 Statistics
Statistical analysis was performed using Origin 8.0 software. ANOVA with a
Bonferroni post-hoc test was used to determine the averages and statistical significance of
data at the p<0.05 level of significance, where applicable. Outliers were determined by
the Grubb’s test and excluded from presented data. All statistically analyzed data is
presented as mean ± standard error.
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3.4

Results

3.4.1 Characterization of S-Nitroso-Penicillamine Modified Ti-6Al-4V
3.4.1.1

Self-Assembled Monolayer Formation on Ti-6Al-4V

The surface of the Ti-6Al-4V metal oxide surface was reacted with COOH-Pa, a
phosphonic acid, to deposit the organic SAM onto the surface of the metal. The addition
of this organic acid presents a more reactive tail group, a carboxylic acid, at the metal
surface.
Methylene stretching peaks for an ordered monolayer are νCH2 asymmetic ≤ 2918 cm-1
and νCH2 symmetic ≤ 2850 cm-1.25, 30, 31, 47 The methylene stretching region of the DRIFT
spectrum of COOH-Pa on Ti-6Al-4V contains two peaks corresponding to the
asymmetric and symmetric CH2 stretches, at 2917 and 2848 cm-1, respectively (Figure
3.3a). The peak positions are indicative of a well-ordered film on the metal surface,
characterized by alkyl chains in an all trans, crystalline-like conformation.25,

31

Additionally, the methylene stretches remain after solvent rinse and sonication, indicating
a stable monolayer of COOH-Pa on the surface of Ti-6Al-4V.25
When using organic acids containing termini of both carboxylic and phosphonic
acid functional groups, the SAM preferentially forms with phosphonic acid as the head
group and carboxylic acid group free at the tail.10, 25, 48 The binding mode of COOH-Pa to
the Ti-6Al-4V surface was also examined using DRIFT (Figure 3.3b). The binding mode
is determined by comparing solid COOH-Pa to that of the COOH-Pa monolayer on Ti6Al-4V.10 The solid COOH-Pa spectrum contains peaks at 1214, 1077, 1008, 951, and
934 cm-1 corresponding to the vP=O, vP-O, asym, vP-O sym, vP-OH, and vP-OH of the phosphonic
acid head group, respectively. The DRIFT spectrum of COOH-Pa bound to the Ti-6Al-
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4V surface contains one broad peak at 1085 cm-1 for vP-O, combined with the loss of both
vP-OH peaks and the vP=O peak suggesting a tridentate binding mode. However, the slight
shoulder off of the broad vP-O peak could suggests some hydrogen bonding between the
oxygen atom of the P=O stretch and the hydrogen of a surface hydroxyl, indicating an
overall mixture of bidentate and tridentate binding is likely occurring (Figure 3.3c).10
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Figure 3.3: DRIFT spectra of the methylene stretching region of COOH-Pa on the
surface of Ti-6Al-4V indicates an ordered, stable SAM (a) and binding region, where the
broad peak at 1085 cm-1 with a slight shoulder in the spectrum of the binding region of
COOH-Pa (b) confirms a mixture of bidentate and tridentate binding (c).

88

3.4.1.2

Immobilization of S-Nitroso-Penicillamine to COOH-Pa Modified
Ti-6Al-4V

The immobilization of S-nitroso-penicillamine to the carboxylic acid tail of
COOH-Pa was completed using carbodiimide coupling. S-nitroso-penicillamine contains
both a carboxylic acid and amine functionality in the same molecule. To avoid undesired
reactions with neighboring molecules, the attachment of S-nitroso-penicillamine was
completed in a two-step process. The carboxylic acid tail on the surface of Ti-6Al-4V
was first activated with EDC and reacted with NHS to form a more sufficient leaving
group for amide bond formation. The formation of a succinimidyl ester at the carboxylic
acid tail indicates successful leaving group formation. The following peaks confirm the
attachment of NHS to the carboxylic acid tail of COOH-Pa: 1813 cm-1 for νC=O for the
NHS ester, 1781 cm-1 for νC=O for the symmetric stretch of the succinimidyl ester within
the ring, and 1740 cm-1 νC=O for the asymmetric stretch of the succinimidyl ester within
the ring (Figure 3.4).49 The stretch at 1210 cm-1 is that of νC-O of the ester group.49
Incomplete activation of the COOH-Pa carboxylic acid tails at the surface can be
observed by the peak at 1722 cm-1 for νC=O.49 Additionally, the stretch at 1556 cm-1 is that
of a formed unreactive side product, N-acylurea.49 The formation of this product is
difficult to prevent under ambient conditions, and thus is ultimately a product in every
carbodiimide coupling reaction.49 After this activation step, the phosphonic acid head
group remains bound the surface in a primarily tridentate manner, based on the P-O
stretch at 1075 cm-1.
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Figure 3.4: EDC and NHS activation of carboxylic acid groups presented at the surface
of the COOH-Pa monolayer on Ti-6Al-4V. Stretches for ester formation at 1813 cm-1,
1781 cm-1, and 1740 cm-1 indicated successful activation of the tail group for further
amide bond formation.
UV-Vis spectroscopy was used to confirm the successful synthesis of S-nitrosopenicillamine. Absorbance maxima at 340 nm and 595 nm are indicative of the electronic
transitions of π → π* and nN → π*, respectively, for the SNO functionality in pure,
unbound S-nitroso-penicillamine (Figure 3.5).50-52 Confirmation of this pure synthesis
allows for further reaction, while the lack of the nitrite and nitrous acid signatures from
the NO donor indicates that no excess nitrite or nitrous acid was present in the samples,
crucial for the success of the NO release assay and the system itself.
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Figure 3.5: UV-Visible spectrum of the unbound S-nitroso-penicillamine liquid NO
donor. The wavelength of maximum absorbance at 342 nm and secondary absorbance at
595 nm confirms successful RSNO formation.
The attachment of S-nitroso-penicillamine to the surface was completed through
the formation of an amide bond. This bond was formed by reacting EDC/NHS activated
Ti-6Al-4V with a solution of the NO donor in ethanol. The attachment of S-nitrosopenicillamine was confirmed by the presence of the νC=O amide I stretch at 1648 cm-1 and
the νN-H amide II stretch at 1575 cm-1 (Figure 3.6). The peak at 1730 cm-1 is that of free
carboxylic acid present in the S-nitroso-penicillamine NO donor, while the stretch at
1510 cm-1 for νN=O indicates that there is NO on the surface of Ti-6Al-4V. The methylene
stretching peaks at 2913 cm-1 and 2847 cm-1 indicate that the COOH-Pa SAM is still
adhered to the Ti-6Al-4V metal oxide surface.
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Figure 3.6: DRIFT spectrum of the attachment of S-nitroso-penicillamine to the COOHPA modified Ti-6Al-4V surface as confirmed by the presence of amide I (1648 cm-1) and
amide II (1575 cm-1). The NO group is present at 1510 cm-1 and the stretch at 1730 cm-1
indicates free carboxylic acid from the S-nitroso-penicillamine donor.

3.4.2 Nitric Oxide Release from S-Nitroso-Penicillamine Modified
Ti-6Al-4V
The total amount of NO released from the surface of NO modified Ti-6Al-4V was
determined using a nitrate/nitrite colorimetric (Griess) assay. Since NO degrades rapidly
into nitrate under physiological conditions, this assay converts nitrates to nitrites, and the
total amount of nitrite is quantified to reflect the amount of NO released.35 The total
amount of NO released by S-nitroso-penicillamine modified Ti-6Al-4V cumulatively
over a 48-hour time period was 89.6 ± 4.8 nmol/cm2 (Figure 3.7). The NO was burst
released between the first and second hour of the assay, followed by a slow release of NO
for the remainder of the assay. The maximum amount of NO released, 77.0 ± 4.8
nmol/cm2, occurred at the two-hour time point.
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Figure 3.7: Quantitation of NO release from S-nitroso-penicillamine modified Ti-6Al4V, determined using the Griess assay. The modified Ti-6Al-4V coupons released 89.6 ±
4.8 nmol NO/cm2 over a 48-hour time period. Each data point expresses the average NO
release ± standard error (n=9).

3.4.3 Antimicrobial Effects of S-Nitroso-Penicillamine Modified
Ti-6Al-4V
3.4.3.1

Antimicrobial Effects of S-Nitroso-Penicillamine

The antimicrobial effect of the unbound, S-nitroso-penicillamine donor was tested
against both E. coli and S. epidermidis via bacterial turbidity. After incubating 0.1
OD600nm E. coli culture with unbound S-nitroso-penicillamine for 2.5 hours, the OD600nm
was collected for the E. coli control and sample. The normalized average OD600nm was
1.00 ± 0.002 for the E. coli control and 0.161 ± 4.0 x 10-4 for E. coli treated with Snitroso-penicillamine, resulting in a 83.9 ± 0.05 % inhibition of E. coli growth (Figure
3.8a).
The unbound S-nitroso-penicillamine NO donor was also tested against
planktonic S. epidermidis culture. After 2.5 hours of growth, the normalized average
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OD600nm was 1.00 ± 0.025 for the S. epidermidis control and 0.283 ± 0.005 for S.
epidermidis treated with S-nitroso-penicillamine, resulting in a 71.6 ± 0.82 % inhibition
of S. epidermidis growth (Figure 3.8b). These results indicate that S-nitroso-penicillamine
is active against both E. coli and S. epidermidis planktonic cultures.
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Figure 3.8: Bacterial turbidity assay of E. coli (a) and S. epidermidis (b) cultures treated
with unbound S-nitroso-penicillamine, shown as mean ± standard error, p<0.05. E. coli
and S-nitroso-penicillamine treated E. coli were statistically different (*). S. epidermidis
and S-nitroso-penicillamine treated S. epidermidis were statistically different (*).

3.4.3.2
3.4.3.2.1

Bacterial Turbidity Tests with S-Nitroso-Penicillamine Modified
Ti-6Al-4V
Escherichia coli

The antibacterial activity of S-nitroso-penicillamine modified Ti-6Al-4V was
assessed by a bacterial turbidity E. coli challenge, where the planktonic growth of E. coli
incubated with Ti-6Al-4V coupons was monitored. The ability of the S-nitrosopenicillamine NO donor to retain it’s antimicrobial ability after covalent attachment to
the COOH-Pa thin film is important for localized, site specific treatment.16 After
incubating a 0.1 OD600nm E. coli culture with Ti-6Al-4V coupons for 2.5 hours, the
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OD600nm was collected for all E. coli controls and samples. The normalized average
OD600nm was 1.00 ± 0.002 for the E. coli control, 0.989 ± 0.007 for the unmodified Ti6Al-4V control, and 0.585 ± 0.011 for S-nitroso-penicillamine modified Ti-6Al-4V
(Figure 3.9). The OD600nm of the E. coli incubated with S-nitroso-penicillamine modified
Ti-6Al-4V was statistically lower than both the E. coli control and E. coli grown with
unmodified Ti-6Al-4V coupons. E. coli growth in the presence of S-nitroso-penicillamine
modified substrates resulted in a 41.5 ± 1.2 % growth reduction compared to the E. coli
control. This confirms that S-nitroso-penicillamine is an active antimicrobial compound
after being immobilized to the Ti-6Al-4V metal oxide surface. Additionally, E. coli
grown with and without Ti-Al-4V coupons were statistically the same, indicating that E.
coli cells are not adhering to the surface of the Ti-6Al-4V coupons.
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Figure 3.9: Bacterial turbidity assay of E. coli cultures treated with S-nitrosopenicillamine modified Ti-6Al-4V shown as mean ± standard error, p<0.05. E. coli and
E. coli grown with unmodified Ti-6Al-4V substrates were not statistically different (#).
E. coli inhibition by S-nitroso-penicillamine modified Ti-6Al-4V is statistically different
(*) than all other groups.
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3.4.3.2.2

Staphylococcus epidermidis

The planktonic growth of S. epidermidis after incubation with S-nitrosopenicillamine modified Ti-6Al-4V coupons was monitored by a bacterial turbidity
challenge. After incubating a 0.1 OD600nm S. epidermidis culture with Ti-6Al-4V coupons
for 2.5 hours, the OD600nm was collected for all S. epidermidis controls and NO modified
Ti-6Al-4V samples. The average OD600nm was 1.00 ± 0.005 for the S. epidermidis
control, 0.985 ± 0.006 for the unmodified Ti-6Al-4V control, and 0.747 ± 0.005 for Snitroso-penicillamine modified Ti-6Al-4V (Figure 3.10). The OD600nm of the S.
epidermidis incubated with S-nitroso-penicillamine modified Ti-6Al-4V substrates was
statistically lower than both the S. epidermidis control and S. epidermidis grown with
unmodified Ti-6Al-4V. S. epidermidis growth in the presence of S-nitroso-penicillamine
modified Ti-6Al-4V resulted in a 25.3 ± 0.6 % growth reduction compared to the S.
epidermidis control. The higher shaking speeds for S. epidermidis growth reduced
bacterial adhesion to the surface of Ti-6Al-4V, as the OD600nm of S. epidermidis and S.
epidermidis grown with unmodified Ti-6Al-4V were statistically the same.
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Figure 3.10: Bacterial turbidity assay of S. epidermidis cultures grown with S-nitrosopenicillamine modified Ti-6Al-4V, shown as mean ± standard error, p<0.05. S.
epidermidis and S. epidermidis grown with unmodified Ti-6Al-4V substrates were not
statistically different (#). S. epidermidis inhibition by S-nitroso-penicillamine modified
Ti-6Al-4V is statistically different (*) than all other groups.

3.4.3.3
3.4.3.3.1

Antibiotic Susceptibility of S-Nitroso-Penicillamine Modified
Ti-6Al-4V
Escherichia coli

The synergistic effect of S-nitroso-penicillamine modified Ti-6Al-4V was tested
with tetracycline against E. coli planktonic cultures. After 2.5 hours, the normalized
average OD600nm for E. coli grown without tetracycline was 1.00 ± 0.002, E. coli grown
with 100 ng/mL tetracycline and unmodified Ti-6Al-4V had an OD600nm of 0.541 ±
0.001, and the average OD600nm for E. coli cultures in the presence of S-nitrosopenicillamine modified Ti-6Al-4V and tetracycline was 0.349 ± 0.007 (Figure 3.11). The
OD600nm of E. coli incubated with S-nitroso-penicillamine modified Ti-6Al-4V and
tetracycline was statistically lower than the E. coli control and E. coli treated with
tetracycline, indicating successful growth reduction. The addition of S-nitroso-
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penicillamine Ti-6Al-4V to an antibiotic increases the effectiveness of tetracycline by
35.4 ± 1.3 %, and thus a synergistic effect was observed.
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Figure 3.11: Antibiotic susceptibility challenge in the presence of E. coli cultures treated
with 100 ng/mL tetracycline and S-nitroso-penicillamine modified Ti-6Al-4V, shown as
mean ± standard error, p<0.05. E. coli treated with S-nitroso-penicillamine modified Ti6Al-4V and tetracycline is statistically different (*) than all other groups.

3.4.3.3.2

Staphylococcus epidermidis

As the NO released from S-nitroso-penicillamine modified Ti-6Al-4V increased
the effectiveness of tetracycline, the same effect was tested with S. epidermidis in the
presence of ampicillin. The concentration of ampicillin used was 0.4 μg/mL, as
determined by testing various concentrations of ampicillin against S. epidermidis (Figure
3.12). This concentration reduced bacterial growth slightly but is not considered fully
inhibitory against S. epidermidis.44
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Figure 3.12: Concentrations of ampicillin tested against S. epidermidis to determine an
appropriate concentration to test for a synergistic effect with S-nitroso-penicillamine
modified Ti-6Al-4V. The desired concentration should be slightly inhibitory as to still
promote the growth of S. epidermidis, and thus 0.4 μg/mL was chosen.
After 2.5 hours, the normalized average OD600nm for S. epidermidis without
ampicillin was 1.00 ± 5.0 x 10-4. S. epidermidis grown with 0.4 μg/mL ampicillin and
unmodified Ti-6Al-4V had an OD600nm of 0.542 ± 0.01 and the average OD600nm for S.
epidermidis grown with S-nitroso-penicillamine modified Ti-6Al-4V and ampicillin was
0.559 ± 0.003 (Figure 3.13). The OD600nm of S. epidermidis incubated with S-nitrosopenicillamine modified Ti-6Al-4V and ampicillin was not statistically different than S.
epidermidis cultures grown with unmodified Ti-6Al-4V and ampicillin, indicating no
synergistic effect against a gram-positive bacteria species.
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Figure 3.13: Antibiotic susceptibility challenge of S. epidermidis cultures treated with
0.4 μg/mL ampicillin and S-nitroso-penicillamine modified Ti-6Al-4V, shown as mean ±
standard error, p<0.05. S. epidermidis grown with S-nitroso-penicillamine modified Ti6Al-4V and ampicillin and S. epidermidis grown with unmodified Ti-6Al-4V and
ampicillin were not statistically different (#), indicating no synergistic effect.

3.4.4 Cytotoxic Effects of S-Nitroso-Penicillamine Modified Ti-6Al-4V
The cell viability of NIH3T3 fibroblasts grown on S-nitroso-penicillamine
modified Ti-6Al-4V was determined using the Live/Dead® Viability/Cytotoxicity Assay.
Live and dead cells were counted on each microscope image and the average percent
viability was calculated.46 The resulting data was normalized to the fibroblasts grown on
unmodified Ti-6Al-4V. The normalized average percent cell viability for fibroblasts
grown on unmodified Ti-6Al-4V and S-nitroso-penicillamine modified Ti-6Al-4V was
100.0 ± 1.3 % and 101.9 ± 1.6 %, respectively (Figure 3.14). Fibroblasts grown on Snitroso-penicillamine modified Ti-6Al-4V had statistically the same percent cell viability
as the unmodified Ti-6Al-4V control, indicating that functionalization of the surface to
release NO did not cause the Ti-6Al-4V substrates to be cytotoxic to mammalian cells.
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Figure 3.14: Normalized average percent cell viability of NIH3T3 mouse embryo
fibroblasts grown on unmodified Ti-6Al-4V and S-nitroso-penicillamine modified Ti6Al-4V. Data is shown as mean ± standard error, p<0.05. Fibroblast growth was not
statistically different between Ti-6Al-4V and NO releasing Ti-6Al-4V (#). The
Live/Dead images of NIH3T3 fibroblasts are below, from left to right: fibroblasts grown
on unmodified Ti-6Al-4V and fibroblasts grown on S-nitroso-penicillamine modified Ti6Al-4V.

3.5

Discussion
NO releasing compounds have not been previously covalently immobilized onto

the surface of metal oxide implant materials but have been incorporated into polymeric
matrices on the metal surface.35-37 Most publications involving NO release from
biomaterials, whether metallic, silicate, or polymeric, utilize potentially carcinogenic
NONOate chemistry.35-37, 53-58 Here, the release of NO from a covalently immobilized
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RSNO donor from the surface of Ti-6Al-4V to reduce E. coli and S. epidermidis growth
and increase the effectiveness of an antibiotic was investigated. This approach has the
potential to be utilized in implant materials to reduce the colonization of bacteria postimplantation, and ultimately prevent implant rejection.
The surface of Ti-6Al-4V was first modified with a COOH-Pa SAM. The
phosphonic acid functional group of the organic acid was bound to the surface of Ti-6Al4V using the thin oxide layer present on the metal surface, acting as the head group of the
SAM. The methylene stretches of the alkyl chain in the DRIFT spectrum indicate that the
alkyl chain is ordered, and in the optimal, crystalline packing orientation on the surface.
This monolayer was also stable to rinsing and sonication in solvent, which are tests for
mechanical and chemical stability. COOH-Pa was bound to the surface in a mixture of
bidentate and tridentate binding, as seen by a broad stretch at 1085 cm-1 in the DRIFT
spectrum with a shoulder indicating possible hydrogen bonding with the P=O of the head
group with the oxide surface.10
The COOH-Pa was bound to the surface using the phosphonic head group, and
thus the carboxylic acid tail groups are presented via the ordered alkyl chain at the
interface for future reactions. This interfacial presentation makes carboxylic acid
available for carbodiimide coupling with the primary amine functionality within the
RSNO donor, S-nitroso-penicillamine, to form an amide bond. Since S-nitrosopenicillamine contains both a primary amine and carboxylic acid functionality, the
COOH-Pa modified Ti-6Al-4V required EDC/NHS activation before reacting with the Snitroso-penicillamine NO donor. Completing the coupling reaction in a single mixture
likely would have caused amide bond formation between individual S-nitroso-
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penicillamine molecules, and not to the surface carboxylic acid groups presented from the
surface. The tail of the COOH-Pa SAM was activated with EDC and NHS to present
NHS at the surface as a more effective leaving group during amide bond formation.
Activation was confirmed by the presence of stretches in the infrared spectrum
characteristic of succinimidyl ester formation.
S-nitroso-penicillamine was synthesized by reacting penicillamine with acidified
nitrite. The synthesis of the RSNO donor was confirmed using UV-Vis, where the
wavelength of maximum absorbance at 340 nm matches that of the characteristic SNO
group of RSNO donors.51, 52, 59 The UV-Vis spectrum of unbound S-nitroso-penicillamine
lacks contributions from excess nitrite and nitrous acid from the synthesis step, and thus
could be utilized in further reactions and NO release assays.60
Reaction of the EDC/NHS activated COOH-Pa modified Ti-6Al-4V coupons with
S-nitroso-penicillamine showed two stretches indicative of amide I and amide II bond
formation in the infrared spectra, indicating successful S-nitroso-penicillamine
attachment to the surface. Additionally, the NO moiety and the unreacted carboxylic acid
group of S-nitroso-penicillamine appearing in the infrared spectrum further confirm
attachment to the metal oxide surface.
The amount of NO released from the surface of S-nitroso-penicillamine modified
Ti-6Al-4V was determined through the Griess Assay, which measures the amount of NO
as it is converted from nitrate to nitrite. From this assay, it was determined that 89.6 ± 4.8
nmol of NO was released per cm2. This amount of NO is less than the μM levels of NO
reported by Gallo et al.,35 but more than the pmole/cm2s amounts reported by Nablo et
al.37 and Holt et al.36 S-nitroso-penicillamine is a tertiary NO donor, which is the most
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stable of the RSNO donors, and is likely responsible for the slow, increasing release of
NO over the 48 time period.
Unbound S-nitroso-penicillamine was found to exhibit inhibitory effects against
both E. coli and S. epidermidis. To generate an antimicrobial surface, S-nitrosopenicillamine should maintain its antimicrobial activity like the original, unbound
molecule once immobilized. The nanomolar amount of NO released from S-nitrosopenicillamine modified Ti-6Al-4V has a bacteriostatic effect against E. coli and S.
epidermidis cultures, as observed from the bacterial turbidity assay. E. coli growth was
inhibited by 41.5 ± 1.2 % when grown in the presence of S-nitroso-penicillamine
modified Ti-6Al-4V, which is significantly different than the E. coli controls (p<0.05)
(Figure 3.9). S-nitroso-penicillamine modified Ti-6Al-4V inhibited S. epidermidis growth
by 25.3 ± 0.6 %, which is significantly different from the other S. epidermidis controls
(p<0.05) (Figure 3.10). S-nitroso-penicillamine is not as bacteriostatic against S.
epidermidis as compared to E. coli, but gram-positive bacteria in general are more
difficult to inhibit with NO.61
A synergistic effect of S-nitroso-penicillamine modified Ti-6Al-4V against E. coli
when coupled with 100 ng/mL tetracycline resulted in a 35.4 ± 1.3 % reduction in growth
when compared to E. coli cultures treated only with tetracycline (p<0.05) (Figure 3.11).
NO is thought to change the physiology of bacterial cells, making them more susceptible
to antibiotics.44 Low concentrations of NO are believed to induce a physiological
transition, where NO converts a stationary phase cell into a more metabolically active
cell.44 Antibiotics target these actively dividing cells, decreasing the population of cells in
a culture, as seen by a decrease in optical density.44
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The NO releasing metal oxide developed here is capable of increasing the
effectiveness of an antibiotic, thus less antibiotic would be needed to treat a bacterial
infection and subsequently reduce the risk of antibiotic resistance.
Unfortunately, S-nitroso-penicillamine modified Ti-6Al-4V when coupled with
ampicillin or vancomycin (data not shown) did not exhibit a synergistic effect against S.
epidermidis (Figure 3.13). Gram-positive bacteria produce their own nM amounts of NO
through bacterial NOS as a defense mechanism to oxidative stress, antimicrobial
treatments, and other bacterial species.61 NO production in a gram-positive bacterial
culture increases as the cells are treated with an antibiotic.61 Thus, the endogenously
delivered nM amounts of NO in the presence of ampicillin does not inhibit bacterial
growth because the bacteria within the culture are already making their own NO.61
To consider this RSNO modified Ti-6Al-4V as a metallic implant material, the
metal surface cannot be cytotoxic to mammalian cells in vitro. Though S-nitrosopenicillamine modified Ti-6Al-4V inhibits bacterial cells, the coupons should not inhibit
NIH3T3 fibroblast growth. S-nitroso-penicillamine modified Ti-6Al-4V showed no
cytotoxic effect to fibroblasts after 24 hours, as the percent viability of fibroblasts grown
on S-nitroso-penicillamine modified Ti-6Al-4V and unmodified Ti-6Al-4V were
statistically the same (p<0.05).

3.6

Conclusions
A RSNO donor was immobilized at the surface of a Ti-6Al-4V metal oxide

implant material using SAMs and carbodiimide coupling. The thin oxide layer on the
surface of Ti-6Al-4V was reacted with organic acid to form a functional monolayer on
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the metal oxide surface. The organic acid presented a carboxylic acid functional group at
the interface, facilitating amide bond formation between the primary amine of S-nitrosopenicillamine (Figure 3.15).
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Figure 3.15: The surface of Ti-6Al-4V metal oxide alloy was modified with a
phosphonic acid SAM and then functionalized at interface to immobilize S-nitrosopenicillamine, a RSNO donor.
The RSNO modified Ti-6Al-4V released nM amounts of NO in vitro and were
bacteriostatic against E. coli and S. epidermidis cultures, indicating that the antimicrobial
activity of S-nitroso-penicillamine remained after immobilization to the Ti-6Al-4V
surface. S-nitroso-penicillamine modified Ti-6Al-4V increased the effectiveness of
tetracycline against E. coli. However, a similar synergistic effect in conjunction with
ampicillin against S. epidermidis was not observed. This may be because Staphylococci
species are capable of producing their own NO when treated with antibiotic. The RSNO
modified Ti-6Al-4V was non-cytotoxic to mammalian cells and thus offers the potential
deliver NO directly to an implant infection site while reducing the amount of antibiotic
needed, limiting the possibility of antibiotic resistance.
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Chapter 4: Conclusions
4.1 Nitric Oxide Delivery From Nanoparticles
Nanoparticles have the ability to deliver drugs and small molecules to a specific
site of infection through inhalation or injection. Unfortunately, a majority of the
developed NO releasing nanoparticles are composed primarily of silica and silica
derivatives. Silica nanoparticles are not approved for use by the FDA and can cause
airway inflammation when inhaled.1,

2

The formulation of biodegradable and

biocompatible nanoparticles composed of PLGA/PVA and RSNOs offer an attractive
alternative for delivery of NO to the lung to combat biofilm infections in a patient with
CF.

4.1.1 S-Nitrosocysteamine Modified Nanoparticles
PLGA nanoparticles, with PVA as the surfactant, were synthesized using a o/w
emulsion technique that presented free hydroxyl groups at the nanoparticle surface. The
hydroxyl groups at the interface of the nanoparticle were reacted with an COOH-Pa, an
organic acid containing both phosphonic and carboxylic acid termini, to form a functional
thin film at the surface. COOH-Pa presented a reactive free carboxylic acid group at the
surface, and was utilized to attach SNC, a RSNO donor, to the exterior of the
nanoparticle. Attachment of SNC to the nanoparticle surface resulted in the release of
37.1 ± 1.1 nmol of NO per mg of nanoparticles under physiological conditions.
The nM amount of NO released from the PLGA/PVA nanoparticles was tested
against bacterial cultures of E. coli. When incubated with E. coli, the SNC modified
nanoparticles inhibited bacterial growth by 31.8 ± 0.7 %, indicating a bacteriostatic effect
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against planktonic cultures. The low concentration of NO released by SNC modified
nanoparticles also exhibited a synergistic effect with a commonly prescribed gramnegative antibiotic, tetracycline. The effectiveness of a ng/mL concentration of
tetracycline when combined with the NO releasing nanoparticles was increased by 87.8 ±
3.3 %. The combination of these NO releasing nanoparticles and an antibiotic provides an
alternative to high doses of antibiotics; here, a low concentration of antibiotic was
combined with a low concentration of NO to inhibit bacterial growth. The use of lower
concentrations of antibiotics can reduce the emergence of antibiotic resistance.3
Unfortunately, this synergistic effect was not observed with SNC modified
nanoparticles and vancomycin against S. epidermidis cultures. Staphylococci species
produce nM amounts of NO through bacterial NOS, and increase NO production when
exposed to oxidative stress, antibiotics, or other bacterial species.4 The exogenous nM
amounts of NO delivered by the SNC nanoparticles were ineffective, as the S.
epidermidis increased their own NO production after being treated with an antibiotic.
The morphology of the nanoparticles did not change after surface reactions, as
confirmed by SEM, and the size of the particles remains at a size that could be suitable
for drug delivery into the human body, including the lungs.5, 6 Nanoparticle size could be
decreased during nanoparticle synthesis by varying concentrations of PLGA or PVA and
by increasing homogenization times/speeds.7 Additionally, the SNC modified
nanoparticles were non-cytotoxic to fibroblast mammalian cells. The nanoparticle size
and non-toxicity make the SNC modified nanoparticles developed here suitable for
inhaled delivery of NO to a CF lung to reduce bacterial infection and systemic antibiotic
usage.
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4.1.2 S-Nitroso-Penicillamine Modified Nanoparticles
S-nitroso-penicillamine modified nanoparticles were not characterized to the
extent of SNC modified nanoparticles, but served as proof of concept for the attachment
of other RSNO donors to the surface of PLGA/PVA nanoparticles. The immobilization of
S-nitroso-penicillamine required a two step attachment process, where the COOH-Pa
carboxylic acid tail was first activated with EDC/NHS and then reacted with the Snitroso-penicillamine donor. The attachment of S-nitroso-penicillamine via amide bond
formation was confirmed in the DRIFT spectrum. Additionally, the wavelength of
maximum absorbance for the S-nitroso-penicillamine modified nanoparticles in the UVVis spectrum matched that of the unbound S-nitroso-penicillamine donor, confirming
attachment. A higher concentration of nanoparticles was required to confirm attachment
via UV-Vis, indicating less NO at the nanoparticle surface compared to the SNC
modified nanoparticles.
The S-nitroso-penicillamine modified nanoparticles when incubated with E. coli
planktonic cultures inhibited bacterial growth by 13.3 ± 2.6%, which is significantly less
than the E. coli inhibition of SNC modified nanoparticles. S-nitroso-penicillamine
modified nanoparticles when combined with tetracycline and E. coli, increased antibiotic
effectiveness by 13.2 ± 1.5 %, indicating a minimal synergistic effect. This further
confirmed that less NO was present at the surface of S-nitroso-penicillamine modified
nanoparticles.
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4.2 Nitric Oxide Delivery From a Metallic Implant Material
As the number of total joint replacements increase in the United States, the
incidences of implant infections continues to rise. As previously mentioned, almost 90%
of all implanted materials show adhesion of pathogenic microorganisms on the surface
prior to implantation.8 Therefore, inhibiting initial bacterial adhesion through antiinfective implant materials would be essential to preventing implant failure and
rejection.9 Antibiotics10-13 and antimicrobial peptides14, 15 have previously been presented
at the surface of metal and ceramic biomaterials using SAMs to reduce bacterial adhesion
and eventual biofilm formation. The use of SAMs to immobilize antimicrobial
compounds chemically alters the outermost layer of the metallic biomaterial, but
preserves the physical properties of the metallic implant.16
Ti-6Al-4V, a metallic implant material utilized commonly in hip and knee joint
replacements, was modified at the surface to release NO from a RSNO.9 The thin oxide
layer that forms spontaneously when exposed to oxygen and water was utilized to form a
COOH-Pa SAM at the metal surface.17, 18 A stable, strongly bound, ordered monolayer
was formed on the surface of Ti-6Al-4V via the phosphonic acid head group, leaving the
carboxylic acid group at the interface for further functionalization. Like the attachment of
S-nitroso-penicillamine to the surface of PLGA/PVA nanoparticles, a two step reaction
process was required to prevent intermolecular amide bond formation. The
immobilization of S-nitroso-penicillamine to the COOH-Pa modified Ti-6Al-4V
proceeded after initial activation of the carboxylic acid tail with EDC and NHS. Amide
bond formation was confirmed using DRIFT spectroscopy, based on the appearance of
amide I, amide II, and NO stretches. The surface of S-nitroso-penicillamine modified Ti-
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6Al-4V released 89.6 ± 4.8 nmole of NO per cm2. These modified Ti-6Al-4V coupons
did not reduce fibroblast adhesion or growth at the surface, indicating that this implant
material could be potentially utilized in vivo.
Unbound S-nitroso-penicillamine was inhibitory against both E. coli and S.
epidermidis cultures at the µM level. Immobilization of S-nitroso-penicillamine to the
surface of Ti-6Al-4V should not change the antimicrobial activity of this donor.
Nanomolar concentrations of NO released from the surface of Ti-6Al-4V were
bacteriostatic against E. coli and S. epidermidis, inhibiting growth by 41.5 ± 1.2 % and
25.3 ± 0.6 %, respectively. Thus, the antimicrobial activity of the S-nitroso-penicillamine
donor remained after immobilization. The low concentrations of NO released from the
surface of S-nitroso-penicillamine modified Ti-6Al-4V also increased the effectiveness of
100 ng/mL tetracycline against E. coli by 35.4 ± 1.3 %, indicating a synergistic effect.
Unfortunately, as with the SNC modified nanoparticles, the S-nitroso-penicillamine
modified Ti-6Al-4V coupons in conjunction with a low dose of ampicillin did not exhibit
a synergistic effect. The combination of the developed NO releasing Ti-6Al-4V implant
material with antibiotic provides an alterative to the systemic doses of antibiotics that are
pre-operatively required, reducing harmful side effects and the potential for bacterial
resistance.19

4.3 Future Work
4.3.1 Antibiotic Susceptibility
Both the SNC modified nanoparticles and S-nitroso-penicillamine modified T6Al-4V did not increase the effectiveness of vancomycin or ampicillin against S.
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epidermidis cultures. These antibiotics are beta lactam antibiotics that are
biosynthetically produced by bacterial species, and can be produced within a mixed
bacterial culture to eliminate other competitive bacterial species.20 The toxicity of these
antibiotics occurs by promoting the formation of reactive oxygen and nitrogen species
within and around the bacterial cell.4,

20

Thus, the delivery of exogenous NO goes

unnoticed in combination with these reactive species generating antibiotics and grampositive bacteria that themselves produce NO.
The addition of an antimicrobial compound not derived from bacterial species
delivered in conjunction with exogenous NO may exhibit a synergistic effect. Barraud et
al. observed an increase in biofilm and planktonic P. aeruginosa inhibition by a
detergent, sodium dodecyl sulfate (SDS), when combined with nM amounts of SNP.21
SDS is a detergent that triggers cell lysis through the disruption or destruction of the
outer cell membrane of bacterial cell (Figure 4.1a).22 Additionally, the ionic nature of
SDS has a high affinity to bind to proteins and denature them.22 A combination of
lysozyme and SDS could prove affective against S. epidermidis cultures, as lysozyme
first hydrolyzes the β(1→4) linkages in the thick peptidoglycan layer of the gram-positive
bacterial cell (Figure 4.1b).22, 23 The mode of action of detergents and enzymes do not
include the formation of reactive nitrogen and oxygen species, and thus may exhibit a
synergistic effect with NO against gram-positive bacteria.

118

(a)
Phospholipid Bilayer

+
O
O S O Na
O

SDS

(b)
Peptidoglycan

O

O
O

OH

O

OH

NH

HO
O

O

NH
OO

R

O
O

O
-H2O

HO

O

O
NH
OO

OH

+

NH

HO
HO

O

O

HO

R
n

R = Peptide
= Lysozyme

Figure 4.1: (a) Mode of action for SDS and (b) lysozyme against bacterial cells.24

4.3.2 Dual Surface Functionalization
Biomaterials developed previously have been dual functionalized to release
multiple bioactive compounds. Palchesko et al. immobilized a cell adhesion peptide and
an antibiotic to create a biomaterial that could promote osseointegration while inhibiting
S. aureus bacterial adhesion during and after implantation.12 Kruszewski et al. dual
functionalized a stainless steel 316L metal oxide implant material to release two
antibiotics, gentamicin and vancomycin, to reduce S. aureus biofilm formation on the
surface.10 Both publications proved that each bioactive molecule was active after
immobilization before dual functionalizing the surface.10, 12
Here, the nanoparticle and Ti-6Al-4V surface could be dual functionalized with
another bioactive molecule, such as an antibiotic, mucolytic agent, or cell adhesion
peptide (Figure 4.2).
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Figure 4.2: The surface of the PLGA/PVA or Ti-6Al-4V surface can be modified to
release NO in conjunction with an antibiotic/antimicrobial peptide (a), a mucolytic agent
(b), or a cell adhesion peptide (c) to form a dual functionalized material.
The immobilization of an antibiotic in conjunction with NO could promote a
synergistic effect, as observed with both surfaces in this work. Here, the nanoparticle or
Ti-6Al-4V surface would simultaneously deliver the NO and the antibiotic, instead of
individually, reducing the need for intravenously or orally delivered systemic antibiotics
(Figure 4.2a). Kruszewski and coworkers immobilized vancomycin and gentamicin
through amide bond formation, but a different orthogonal chemistry would be required to
maintain the RSNO attachment developed here.10 This can be done through the use of
different organic acid thin films containing different tail groups. The nanoparticles could
also be dual functionalized to deliver NO and an antibiotic through the o/w emulsion
synthesis technique. Here, an antibiotic could be encapsulated within the PLGA core of
the nanoparticle, and then surface functionalized to release NO (Figure 4.3).25
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Figure 4.3: Antibiotic encapsulation within the PLGA core of PLGA/PVA nanoparticles,
with NO immobilized on the nanoparticle surface.
In potential applications of NO delivery to the lungs, the nanoparticle surface
could be functionalized with a NO and a mucolytic agent such as dithiothreitol (DTT) or
N-acetylcysteine (NAC) (Figure 4.2).26, 27 DTT and NAC are commonly prescribed for
individuals with CF, as it promotes the detachment of the thick mucus within a CF
patient’s airway. Nanoparticle delivery to the CF lung could be complicated by this
mucus layer in the airway, where the particles could be trapped within the airway and not
disperse to the bacterial biofilms in the lower airway.
Osseointegration of the NO releasing Ti-6Al-4V could be improved through dual
functionalization with NO and a cell adhesion peptide (Figure 4.2c). Palchesko and coworkers observed that osteoblast adhesion was improved upon attachment of the cell
adhesion peptide lysine-arginine-serine-arginine (KRSR) to a calcium aluminate bone
scaffold.12 Additionally, arginine-glycine-aspartic acid (RGD) was immobilized to the
surface of Ti-6Al-4V metal oxide to enhance osteoblast attachment and spreading.28

121

Developing an implant material that contains a cell adhesion peptide and NO would
promote osseointegration while preventing bacterial adhesion to the metal oxide implant
surface.9

4.4 Project Impact
Due to increased incidences of antibiotic resistance, alternative antimicrobial
compounds are required to ensure the long-term effective treatment for bacterial
infections.29 An antibiotic alternative, NO, is an effective antimicrobial compound
against both gram-positive and gram-negative bacterial species, and has been released
through a variety of polymeric,30-34 silicate,1,

35-38

and metallic39-41 biomaterials.

Unfortunately, most of these developed biomaterials utilize potentially carcinogenic
NONOate NO donors instead of RSNO NO donors naturally produced by the human
body. The development of a drug delivery vehicle or biomaterial capable of delivering
naturally derived NO donors directly to the site of infection would significantly reduce
the amount of systemic antibiotic usage, limiting the possibility of antibiotic resistance.9
Here, a PLGA/PVA nanoparticle drug delivery vehicle and an implant
biomaterial, Ti-6Al-4V, were modified at the surface to release amounts of NO that were
bacteriostatic against E. coli and S. epidermidis planktonic cultures, while simultaneously
increasing the effectiveness of traditionally prescribed antibiotics. These materials could
reduce the usage of systemic antibiotics, as the antimicrobial delivery of NO is delivered
directly to the site of infection. Unlike antibiotics, there has been limited observed grampositive and gram-negative bacterial resistance to exogenously delivered NO, likely due
to the multiple mechanisms of NO bacterial toxicity.42
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